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Introduction 
  I.  INTRODUCTION 
CATARACT 
Cataract is an eye disease in which the clear lens of the eye becomes cloudy or opaque, 
causing a decrease in vision. Although the word cataract to describe this condition has been 
part of the English language since only the 15th century, the eye disease has been recognized 
and surgically treated since ancient times. 
According to WHO: “Cataract is clouding of the lens of the eye which impedes the passage 
of light. Although most cases of cataract are related to the ageing process, occasionally 
children can be born with the condition, or a cataract may develop after eye injuries, 
inflammation, and some other eye diseases.”The lens is a portion of the eye that is normally 
clear. It focuses rays of light entering the eye onto the retina, the light-sensitive tissue at the 
back of the eye. In order to get a clear image onto the retina, the portions of the eye in front 
of the retina, including the lens, must be clear and transparent. The light striking the retina 
initiates a chemical reaction within the retina. The chemical reaction, in turn, initiates an 
electrical response which is carried to the brain through optic nerve. The brain then interprets 
what the eye sees. 
In a normal eye, light passes through the transparent lens to the retina. The lens must be clear 
for the retina to receive a sharp image. If the lens is cloudy from a cataract, the image striking 
the retina will be blurry or distorted and the vision will be blurry. The extent of the visual 
disturbance is dependent upon the degree of cloudiness of the lens. 
Most cataracts are related to ageing. Cataracts are very common in older people. By age 80, 
more than half of all Americans either have some degree of cataract or have already 
undergone cataract surgery in one or both eyes. By age 95, this percentage increases to 
almost 100%. A cataract can occur in either or both eyes. Individuals with a cataract in one 
eye usually go on to develop a cataract in the other eye as well. A cataract is 
not contagious and cannot spread from one eye to the other or from person to person. 
Cataracts do not cause the eye to tear abnormally. They are neither painful nor make the eye 
itchy or red. 
Although vision can be restored in most people with cataracts, age-related cataracts are still 
the most common cause of blindness in the world, primarily because many third-world 
nations lack appropriate and available surgical services. 
Fig.1 
 
Fig.  2 
DIFFERENCE BETWEEN NORMAL VISION AND CATARACT VISION 
 
 
 
 
Fig.3 
 
LENS – NORMAL  &  CATARACT  
 
TYPES OF CATARACT 
 
 Nuclear cataracts, which form in the lens' nucleus, are the most common type of cataracts. 
Because opacity develops in the centre of the lens, known as the central nucleus, nuclear 
cataracts interfere with a person's ability to see objects in the distance. Usually the result of 
advancing age, nuclear cataracts can take years to develop and often give the nucleus a 
yellow tint. 
 
 Cortical cataracts begin at the outer rim of the lens and gradually work toward the central 
core. Thus, this type of cataract resembles spokes of a wheel. Patients with cortical cataracts 
often notice problems with glare, or a "halo" effect around lights. They may also experience a 
disruption of both near and distance vision. 
 
 Subcapsular cataracts progress the most rapidly. While nuclear cataracts take years to 
develop, subcapsular cataracts reach an advanced stage within a matter of months. Posterior 
subcapsular cataracts affect the back of the lens, causing glare and blurriness. This type of 
cataract is usually seen in patients who suffer from diabetes, extreme nearsightedness or 
retinitis pigmentosa, as well as among those who take steroid medication. 
 
 Congenital cataracts refer to cataracts that are present from birth, as well as to those that 
develop in early childhood. These cataracts can be nuclear, cortical, or subcapsular. 
Congenital cataracts may be linked to an infection contracted by the mother during pregnancy 
or to a genetic condition such as Fabry disease, Alport syndrome, or galactosemia. Because 
clear vision is essential to the development of the child's eyes and brain, it is important to 
diagnose congenital cataracts as early as possible. 
 
 Secondary cataracts are caused by disease or medications. Diseases that are linked with the 
development of cataracts include glaucoma and diabetes. The use of the steroid prednisone 
and other medications can sometimes lead to cataracts. 
 
 Traumatic cataracts develop after an injury to the eye, but it can take several years for this 
to happen. 
 
 Radiation cataracts can form after a person undergoes radiation treatment for cancer. 
Because each of these cataract types affects vision in a distinct manner, it is possible for a 
patient to have more than one type of cataract at the same time. 
 
STAGES OF CATARACT 
Early Stages of Cataracts 
 
When cataracts first develop, they are typically small enough that they don’t impair vision. 
However, if left untreated, cataracts can lead to bigger vision problems. To help you preserve 
your eyesight, it’s best to catch and treat this issue in its early stages. 
  
The first signs of cataracts typically include slightly blurred vision, faded colors, minor loss 
of night vision, and halos around lights. Other symptoms in the early stages of cataracts 
include an increase of glare and double vision. 
 
On top of that, a person with cataracts may have a more difficult time adjusting when going 
from a brightly lit room to a darker one. This is because a cataract can cause decreased 
contrast sensitivity, or the eye’s ability to adjust to different light levels intensities. 
When a cataract forms, it will also continue to grow and affect your vision. If your eyesight 
seems to be getting worse to a point where you need stronger prescriptions for eye glasses 
and contact lenses, contact your doctor as this could be an early sign of cataracts. 
 
Advanced Stages of Cataracts 
 
As cataracts progress, symptoms will increase and become more severe. In the advanced 
stages of cataracts, it becomes more difficult to see clearly. Your vision will become cloudier, 
especially during the day. You may also see a visible white spot on the lens of the eye and 
milky or yellowish pupils. 
 
In some rare cases, an advanced cataract can start to leak into other parts of the eye. This can 
lead to inflammation, pain, and most significantly, complete loss of eyesight. 
 
Signs and symptoms of cataracts include: 
 Clouded, blurred, foggy or dim vision 
 Increasing difficulty with vision at night 
 Sensitivity to light and glare 
 Need for brighter light for reading and other activities 
 Seeing "halos" around lights 
 Frequent changes in eyeglass or contact lens prescription 
 Fading or yellowing of colors 
 Double vision in a single eye 
 Near sightedness (in older people) 
 Problems with glare during the day 
 Double vision in the affected eye 
 
 
Risk factors 
Factors that increase your risk of cataracts include: 
 Increasing age 
 Diabetes 
 Excessive exposure to sunlight 
 Smoking 
 Obesity 
 High blood pressure 
 Previous eye injury or inflammation 
 Previous eye surgery 
 Prolonged use of corticosteroid medications 
 Drinking excessive amounts of alcohol 
 Statin medicines used to reduce cholesterol 
 Hormone replacement therapy 
 Significant alcohol consumption 
 High Myopia 
 Family history 
 
Causes 
Most cataracts develop when ageing or injury changes the tissue that makes up the eye's lens. 
Some inherited genetic disorders that cause other health problems can increase your risk of 
cataracts. Cataracts can also be caused by other eye conditions, past eye surgery or medical 
conditions such as diabetes. Long-term use of steroid medications, too, can cause cataracts to 
develop. 
Pathophysiology 
Changes in the lens proteins (crystallins) affect how the lens refracts light and reduce its 
clarity, therefore decreasing visual acuity. Chemical modification of these lens proteins leads 
to the change in lens colour. New cortical fibres are produced concentrically and lead to 
thickening and hardening of the lens in nuclear sclerosis, which often appears yellow and can 
increase the focusing power of the natural lens. Increasing myopia can also be evidence of a 
progressing nuclear sclerotic cataract. In an experimental model, oxidative stress contributed 
to cataract formation, causing a decrease in the level of adenosine triphosphate and 
glutathione disulfide.  
 
Cortical cataracts are most often seen as whitish spokes peripherally in the lens, separated by 
fluid. Vacuoles and water clefts can also be seen in these lenses. Posterior subcapsular 
cataracts are due to the migration and enlargement of lens epithelial cells (Wedl cells) 
posteriorly. Diabetes mellitus is a major factor in the formation of this type of cataract. 
Osmotic stress due to sorbitol accumulation has been linked with sudden worsening in 
patients with uncontrolled hyperglycemia. However, research has also found that when 
sorbitol dehydrogenase was blocked, preventing sorbitol accumulation, oxidative stress was 
connected with slow-developing cataracts. 
 
Aetiology 
Although the most common cause of cataract is the normal ageing process, other conditions 
that can contribute to opacification of the lens include trauma, metabolic disorders (hereditary 
or acquired), infections (e.g., rubella), medications, or congenital problems. While there is 
still some debate, smoking, alcohol, and exposure to UV radiation have also been indicated as 
factors that may cause cataract progression, especially nuclear sclerotic cataracts. 
 
Etiopathogenesis 
Clinically, cataract patients can be classified into morphological groups viz. nuclear, sub-
capsular or cortical for studying the risk factors. Most case-control studies have been on 
pooled cataracts. This approach has been strongly criticized by some authors on the basis that 
different morphological types have different risk factors. Since cataract is a major cause of 
avoidable blindness in the developing countries, the key to the success of the Global Vision 
2020: The right to sight initiative is a special effort to tackle cataract blindness by finding out 
precise cause. Even though effective surgical procedures are available for treatment, the 
problem of post-operative complications, cost of surgery, and high number of people 
requiring surgery pose a substantial economic burden. 
It has been estimated that delaying cataract onset by 10 years could reduce the need for 
surgery by as much as half. The respective causes of different type of cataracts must be 
known in order to understand the patho-physiology of disease and its management. However, 
risk factors for cataracts summarized above cannot be comprehended this way, but they may 
help to confer the matter with new approaches.         
Inherited disorders are often involved in the development of congenital cataracts in children 
with ratio of 1:10,000 births. Such cataracts are most often due to inborn abnormalities in the 
structure or shape of the lens capsule. PITX3 gene has been reported as responsible for some 
inherited cataracts. The role of Osaka variant is new interest of point at present. Infantile 
cataracts, those developing within the first year of life, are frequently associated with a 
metabolic or systemic disease. The role of gender and race or community could not be made 
clear in the development of cataract. Age-related cataracts are mostly developed due to 
increase in oxidative stress in lens due to various systemic diseases or imbalance in pro and 
anti-oxidants in body particularly eyes. 
Trauma has direct impact to induce denaturation processes in eye lenses. Removal and 
implant placement can be complicated in these cases though, as the blunt force often tears the 
zonular support. Complications of untreated systemic as well as local conditions are well-
elaborated in development of cataract, though their mechanism is still unclear. 
Cataracts, those precede by metabolic abnormalities, are mostly associated with congenital 
aberrations. Most of them are having peculiar diagnostic characters like oil droplet type of 
opacity appearance in galactosemia, multicoloured crystals-like opacities can be seen in 
hypocalcemia and sunflower-like appearance in copper metabolic error. The deficiencies of 
micronutrients directly affect the antioxidant systems in eyes lens. The role of nutrition in 
cataract formation in developing countries is perhaps closely linked with diarrhoea and 
poverty, all of which are closely interrelated.  
Many drug abuses as well as various toxins may cause oxidative damage and interrupt the 
lens growth. They bind to sulfhydryl groups, including glutathione peroxidase and 
N
a+
 K
+
 ATPase, along with super oxide dismutase and catalase, which are responsible for the 
maintenance of clarity of the lens during oxidative stress. Most of them are reversible in 
nature. 
 Radiation stimulates the senile changes in eye lenses. Radiation or electromagnetic waves 
can rouse the exfoliation process in lens that leads to disturbance in protein arrangement and 
oxidative systems. Experimental evidence indicates maximum lens sensitivity to UVR-B in 
the wavelength region around 300 nm. ROS are mediators of damage induced by UVR and 
can trigger alteration in growth factors- and cytokine-mediated signal transduction pathways, 
leading to aberrant gene expression. 
   
Elimination of causes of cataract which were described above may reverse the cataractous 
changes in the initial stage. Nutritional supplements and balancing antioxidants during old 
age and malnutrition and in condition of diarrhoea are reported in preventing senile cataract. 
Correction of transient metabolic defects e.g., treatment of galactosemia, copper metabolism 
etc., are also found useful in the prevention of cataract. Eluding factors affecting congenital 
defects like consanguineous marriage, galactosemic diet, medication and radiation during 
pregnancy can be helpful in preventing development of congenital cataract.   
Prescription of alternate medications for steroid and other drugs prone to cataract formation 
can be used to prevent cataractous changes. Many studies reported that antioxidants (Vit E, 
Vitamin- C, thiamine, riboflavin, lutein, flavonoids, carotenoids etc.) can effectively prevent 
and cure UVB-induced protein oxidation and photo-peroxidation of lipids in lens. Local 
protective measures like use of UV-protected sun glasses as well as use of UV-absorbing 
hydrogel polymers also can be useful in this way. Though many of the factors identified are 
responsible for the development of cataract, but their mechanism of action is still unclear.  
 
How a cataract forms 
The lens, where cataracts form, is positioned behind the colored part of your eye (iris). The 
lens focuses light that passes into your eye, producing clear, sharp images on the retina. As 
one ages, the lenses become less flexible, less transparent and thicker. Age-related and other 
medical conditions cause tissues within the lens to break down and clump together, clouding 
small areas within the lens. 
As the cataract continues to develop, the clouding becomes denser and involves a bigger part 
of the lens. A cataract scatters and blocks the light as it passes through the lens, preventing a 
sharply defined image from reaching your retina. As a result, the vision becomes blurred. 
Cataracts generally develop in both eyes, but not evenly. The cataract in one eye may be 
more advanced than the other, causing a difference in vision between eyes. 
Diagnosis 
Cataracts are fairly easy to diagnose. Nevertheless, for the most accurate diagnosis, there are 
a number of advanced tests that your doctor may use. Utilizing these diagnostic tools, your 
doctor can also check for an additional eye disease, such as glaucoma or macular 
degeneration. 
 
Visual Acuity Test 
 
 
 
 
 
The visual acuity test is used to determine the smallest letters one can read on a 
standardized chart (Snellen chart) or a card held 20 feet (6 meters) away. Special charts are 
used when testing at distances shorter than 20 feet (6 meters). Some Snellen charts are 
actually video monitors showing letters or images. This test allows detection of any 
significant changes in the vision. 
 
If one is already been diagnosed with cataracts, and the vision has degenerated to 20/40 or 
below, doctor may recommend surgery. In some cases, one may have a good score on this 
test, but may still present with other cataract symptoms, such as light sensitivity or blurred 
vision. When this occurs, ophthalmologist will likely recommend more tests to determine 
whether cataracts are, in fact, responsible for those symptoms. 
 
Slit Lamp Exam 
 
Surgeon will give eye drops to dilate the pupil. By shining a light on the front of the eye, we 
can usually detect any white spots on the lens, even if they are very minute. The slit lamp 
exam often allows for extremely early diagnosis, so that an ophthalmologist can detect 
cataracts before they begin to affect the vision. 
 
During the test, the surgeon will likely use a magnifying lens to examine the retina and optic 
nerve. Although this step is not necessary for cataract detection, it enables surgeon to check 
for other serious eye conditions. 
Retinal Exam 
To prepare for a retinal exam, eye surgeon puts drops in the eyes to dilate the pupils wide. 
This makes it easier to examine the retina. Using a slit lamp or an ophthalmoscope, eye 
surgeon can examine the lens for signs of a cataract. 
Glare and Contrast Sensitivity Tests 
 
These two tests are similar to a traditional visual acuity test. 
 
During a Glare test, they will be asked to read the Snellen chart under various lighting 
conditions. If we have difficulty discerning the letters under very bright light, this could be a 
good indication of cataracts. The Contrast sensitivity tests use different kinds of charts; 
instead of the letters getting smaller as they go down the chart, they "fade," or contrast less 
with the white background. If we are unable to read all but the most defined rows of letters, 
this, too, could be an indication of cataracts. 
 
Ishihara Color Test 
 
Named after its designer, Dr.Shinobu Ishihara, this test uses a series of plates covered with 
colored dots. The dots vary in color, forming a number in the centre of the plate. Those with 
an inability to distinguish hues on the blue-green end of the spectrum will not be able to see 
the numbers. If have not been previously diagnosed as color blind, and we do not pass the 
Ishihara color test,  may be suffering from advanced cataracts. 
 
Tonometry Test 
 
Ophthalmologist will direct a puff of air towards the eye, and it will measure the intraocular 
pressure (IOP), determined by the amount of vitreous fluid inside the eye. Although 
tonometry tests are most commonly used to diagnose glaucoma, it is important that eye 
surgeon be as thorough as possible during cataract diagnosis. When left undiagnosed and 
untreated, glaucoma, macular degeneration, and similar eye diseases can have dramatic 
consequences for our vision and ocular health. 
 
Treatment for Cataracts 
 
The prescription glasses can't clear the vision, the only effective treatment for cataracts is 
surgery. In the beginning stages of cataracts, vision may be slightly improved using forms of 
visual correction. However, in the later stages, surgery may be required. Fortunately, surgery 
has proven to be extremely successful in the removal of cataracts. During cataract surgery,  
physician will replace the natural lens with an IOL. 
Patients' responses to the presence of a cataract vary. A cataract in only one eye may be 
disturbing to a particular patient and may not cause significant symptoms in another patient. 
Cataracts usually do not harm our eye, so we can have surgery when it is convenient for us 
and when the cataract interferes with our daily activities. Once we understand the benefits 
and risks of surgery, we can make an informed decision about whether cataract surgery is 
right for us. In most cases, delaying cataract surgery will not cause long-term damage to the 
eye or make the surgery more difficult. 
If the eye has other diseases that have caused visual loss such as glaucoma, macular 
degeneration, diabetic retinopathy, or optic nerve damage from glaucoma or other diseases, 
cataract surgery may not improve the vision. 
 If both eyes have cataracts and surgery is agreed upon, the surgery on the second eye is 
generally planned at least a week after the first eye. There is usually no harm in waiting a 
much longer period of time between the two eye surgeries. Because the lens of the eye is 
necessary to accurately focus light onto the retinal surface and removal of the cataract 
involves removal of the lens, modern cataract surgery combines removal of the lens and 
placement of a new artificial lens into the eye. Measurements for the size, shape, and power 
of this lens will be taken prior to the surgery so that the specific lens can be available for 
implantation at the time of surgery. 
It's up to the surgeon to decide when cataract surgery is right for the patient. For most people, 
there is no rush to remove cataracts because they usually don't harm the eye. But cataracts 
can worsen faster in people with diabetes. Delaying the procedure generally won't affect how 
well the vision recovers if we later decide to have cataract surgery. Therefore it is advised to 
take time to consider the benefits and risks of cataract surgery with the surgeon. 
Cataract surgery 
Cataract surgery involves removing the clouded lens and replacing it with a clear artificial 
lens. The artificial lens, called an intraocular lens (IOL), is positioned in the same place as the 
natural lens. It remains a permanent part of the eye. For some people, other eye problems 
prohibit the use of an artificial lens. In these situations, once the cataract is removed, vision 
may be corrected with eyeglasses or contact lenses. 
Cataract surgery is generally done on an outpatient basis, a day-care procedure. During 
cataract surgery, eye surgeon uses a local anesthetic to numb the area around the eye, and the 
patient usually stays awake during the procedure. Cataract surgery is generally safe, but it 
carries a risk of infection and bleeding. It also increases the risk of retinal detachment. After 
the procedure, the patient will have some discomfort for a few days. Healing generally occurs 
within eight weeks. If cataract surgery is needed in both eyes, the surgeon will schedule 
surgery to remove the cataract in the second eye after having healed from the first surgery. 
The purpose of the lens is to refract light rays that come into the eye to help us see. Having a 
cataract can be like looking through a foggy or dusty car windshield. Things may look blurry, 
hazy or less colourful. 
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CATARACT SURGERY 
PHACOEMULSIFICATION 
Phacoemulsification, introduced by Kelman in 1967, is undoubtedly one of the most 
important innovations in ophthalmology. This has now been accepted as gold standard 
surgical procedure for management of cataract. this allows the removal of cataract through a 
3.0 mm incision, thus eliminating many of the complications of wound healing related to 
large incision surgery and greatly shortens the recovery period. 
Preoperative preparation 
 
All the basics of ECCE like full mydriasis, good anaesthesia, antimicrobial preparation of 
operative part, use of disposable plastic drape are to be given due importance. 
 
Patient Selection 
 
The current technique and equipment have developed to such an extent that this technique 
may be used in majority of cases of cataract. However preoperative evaluation of patients 
under full mydriasis with slit-lamp examination is very important. This will give valuable 
information about pupillary dilation, grade of nuclear sclerosis and zonular support. 
Sometimes evaluation of fundus is possible, and will assure you a good post operative vision 
in case of uneventful surgery. 
Relative contraindications are miotic pupil which refuses to dilate, very hard nucleus and lack 
of zonular support. For a beginner, ideal case is patient of around 60 years with moderate 
hardness and good fundal reflex.  
 
Following are difficult situation for phacoemulsification: 
 
  Deep set eyes 
  Shallow eyes 
  Hazy cornea 
  Non dilating pupil 
 Brunescent cataract Grade IV/V or very soft cataract 
 Subluxated/ dislocated lens 
 Cataract in vitrectomized patient 
 
Hardness of Nucleus 
 
 
Utmost importance should be given to assessment of the hardness of the nucleus. This can be 
assessed with slit-lamp examination under mydriasis. Nucleus of crystalline lens changes 
from transparent to gray to gray-yellow amber, brown and finally to almost black. To a 
certain degree, variation in colour corresponds to an increase in hardness of nucleus. Other 
important consideration is patient age. Older the patient harder the nucleus is likely to be.  
 
Hardness of nucleus can be classified as follows: 
 
1. Soft nucleus (Grade 1) - transparent to pale gray 
2. Slightly hard nucleus (Grade 2) gray - greyish yellow 
3. Moderately hard nucleus (Grade 3) - yellow with tinge of gray 
4. Hard Nucleus (Grade 4) - Yellow amber 
5. Very hard Nucleus (Grade 5) - brown-black 
 
PHACOMACHINE 
 
Ultrasonic handpiece: Ultrasonic power is most often produced by enclosed piezoelectric 
crystals which convert electricity into mechanical vibration. This energy is transmitted along 
the handpiece into phaco-needle in such a way that primary oscillation is axial. Irrigating 
fluid flows through two ports located 180° apart on the silicon sleeve surrounding the phaco 
tip. 
 
Fluid flows between needle and silicon sleeve. Normal frequency of various phaco machines 
ranges from 20,000 to 80,000 (20-80 KHz) Hertz. Frequency is fixed for particular machine. 
Usually it is in the range of 40 KHz. Stroke length is the forward and backward movement of 
the needle along the longitudinal axis. These oscillations are between 70-120 microns wide. 
This can be varied by selecting different power limits. 
 
Phaco tips - These are made up to titanium. It can have an opening angulation of 0°, 15°, 
30°, and 45°. Greater angulation facilitates sculpting whereas lower angle is good for 
occlusion. 30° tip is suitable for both functions and is the most preferred one. External  
 
diameter of needle is 1.1 mm and internal diameter is 0.9mm. In case of microtip needle 
external diameter is 0.9 mm and internal diameter is 0.5-0.7 mm. The tip is covered with 
silicon sleeve that insulates and protects the tissue at the incision site. 
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PHACO TIP 
 
FLUID DYNAMICS 
 
Aspiration flow rate: The quantity of liquid (measured in cubic centimeters = CC) which 
circulates in unit time (one minute) is defined as flow. The liquid flows downward sunder 
gravity from the infusion bottle, passes through infusion line and reaches the eye through 
handpiece. It exits the eye through the aspiration line and also through main and side port 
incision (leakage). The flow of fluid is mainly responsible for bringing the nucleus fragments 
towards the phaco tip. 
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PUMPS 
Pumps create the vacuum during the aspiration flow. There are basically three different types 
of pumps used in phaco machines. 
 
1. Peristaltic pumps 
Peristaltic pumps have been used the longest. A peristaltic pump creates aspiration by 
advancing fluid through a tube that is wound tightly around a 'humped' rotating wheel. It 
works by squeezing off small segments of the tubing between successive rollers mounted on 
a wheel. As the wheel turns the segment of fluid trapped between two rollers is moved, 
creating a vacuum behind that is relieved by more fluid coming up the tubing. 
 
With a peristaltic pump, flow rate depends on pump speed when the tip is not occluded. 
Aspiration vacuum builds when the tip is partially or totally occluded, andonce again the rate 
of rise of the vacuum depends on the pump speed. The vacuum level limit and the flow rate 
(vacuum rate of rise) can be adjusted independently with peristaltic pumps. The vacuum level 
can be adjusted by setting the transducer to allow for venting at a certain limit. The flow rate 
is determined by setting a limit to the rotation speed of the peristaltic pumps. Also, if the 
surgeon desires, both the vacuum limit and the flow rate can be varied by linear control, 
which is the instantaneous change of each parameter by depression of the foot pedal. 
  
2. Vacuum Pumps 
The evacuation of air from a closed container by a vacuum pump can be used to form a 
vacuum reservoir. This vacuum reservoir can create a flow in the aspiration tubing. The two 
styles of vacuum pumps are ‘diaphragmatic' or 'venturi'. 
 
Venturi pump 
This is driven the compressed gas (nitrogen or air) that is directed through the chamber. By 
varying the size of the opening, the volume of the gas through the chamber is proportionately 
controlled. The gas flow over the opening of tube into chamber creates a pressure differential 
via a venturi effect with air flow. This air flow and pressure differential in the tube creates a 
vacuum in the chamber that pulls fluid in from the aspiration tubing. Vacuum and flow rate 
are proportionately linked on a venturi pump and cannot be independently adjusted as they 
can on a peristaltic pump. 
 
FOOT SWITCH 
Phaco machines come with a foot switch to control functions of the machine. Newer 
machines can almost be totally controlled with the foot switch. The basic control positions 
are the same with all machines. In the ultrasound mode (U/S), on depressing the foot pedal, 
the position entered first is ‘position 1’( Fig. 7) . In this position, the irrigation line is opened, 
with free flow out of the phaco tip sleeve. On further depressing the foot pedal, aspiration is 
initiated and vacuum is transmitted to the phaco tip. This is ‘position 2’. Further depression 
of the foot pedal activates the ultrasound oscillation of the phaco tip, generating the force 
required to emulsify the nucleus. The foot pedal control is linear in the sense that the power 
generated is proportional to the amount by which the foot pedal is depressed. 
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FOOT SWITCH POSITIONS 
 
Foot switch positions 
1 - Irrigation on; 2 - Vacuum on; 
3 - U/S Power on 
 
 
Surge and venting 
Surge is a phenomenon encountered in position 2 or 3 when an occluded fragment at the 
phaco tip is aspirated and suddenly occlusion is broken. Because of higher pressure in 
anterior chamber (AC) fluid suddenly rushes to lower pressure in phaco tip, creating a 
potential for AC collapse which could damage the cornea or posterior capsule. Newer 
machines have effective anti surge designs. Venting is the main anti collapse system. In this 
case the negative pressure inside the aspiration line is neutralized with emission of liquid or 
air. 
 
 INCISION CONSTRUCTION 
Ideal incision for phacoemulsification should be astigmatically neutral and free from sutures. 
There are following different parameter in relation to incision: 
1. Position (a) with regard to limbus(b) with regard to o’clock position 
2. Size 
3. Shape 
Position with regard to the limbus, three sites can be chosen for incision. 
1. Sclero-corneal 
2. Limbal 
3. Clear corneal 
 
Sclero corneal 
As one moves away from centre of the cornea, surgically induced astigmatism is minimized. 
A large incision (5.5 mm) is also possible at this site. However, there are a number of 
disadvantages associated with this type of incision. 
1. Conjunctiva must be reflected. Diathermy is a must 
2. Greater time is required 
3. Difficulty is manipulating of instrument in A.C. 
Incision is constructed about 2mm away from limbus after reflecting the conjunctiva and 
applying diathermy. With blade or Bard Parker knife, a vertical partial thickness sclera 
incision is given. With crescent knife, dissection is made in sclera and cornea and finally is 
entered with a 3 mm keratome. 
 
Limbal incision 
Limbal incision is one where external edge is localized 0.5mm posterior of vascular arcade 
that is on fixed conjunctiva. These incisions are also called as ‘near clear incision’. 
 
Advantages of limbal incision are: 
a) They induce less astigmatism as away from visual axis 
b) They heal rapidly as they have a vascular support 
c) It has a water tight shape and offers greater resistance to pressure as compared to a clear    
    corneal incision 
 
 
Disadvantages are: 
a) Greater possibility of ballooning of conjunctiva which can lead to poor visibility in AC 
b) Increased risk of subconjuctival haemorrhage 
 
Clear corneal incision 
The incision is considered to be clear corneal when its external wound is positioned anterior 
to limbal vascular arcade (0.5mm anterior to limbus).  
 
Advantages of clear corneal incision are : 
a) It eliminates need to manipulate the conjunctiva 
b) Aesthetically satisfactory result as eye does not appear to be operated 
c) Intra-operatively tunnel is visible and manipulation of instruments in anterior chamber is 
easier 
d) Requires less time and fewer instruments 
 
Disadvantages: 
a) Poor stability : Any incision more than 4 mm without suture may be unstable 
b) Post operative endophthalmitis. There may be increased chance of endophthalmitis. 
Clear corneal incision are invaluable in presence of filtering bleb, patients with coagulation 
disorders, patients with history of alcohol abuse and finally, while operating under topical 
anesthesia. 
 
Position 
With respect to corneal curvature, the incision can be positioned in: 
a) Temporal quadrant 
b) Superior quadrant 
c) Obliquely (Superotemporal quadrant) 
d) In axis of greatest curvature 
 
The choice of position depends on two factors, induced astigmatism and the ergonomics of 
the operation. Until a few years ago, an incision in the superior quadrant was the most 
popular. It causes slightly more astigmatism (ATR) than its temporal counterpart. 
 
Nowadays, this site is generally used for making sclero-corneal incision. Clear corneal 
temporal incision is the most favored incision with the majority of surgeons. It produces least 
or no astigmatism, easier access to surgical zone, good red reflex and it facilitates the 
drainage of irrigating solution. 
 
 
Dimensions 
The size of incision depends upon the size of lens to be implanted. It varies from 2.8 to 4 mm 
for foldable lenses and 5.5 to 6.5 for rigid lens. In foldable category, it also depends upon the 
size of phaco probe which may vary from 2.8 to 3.2 mm. Size of entry wound should match 
with size of phaco probe. Any incision in clear cornea more than 4 mm should be sutured. 
 
 
Paracentesis (Side port) 
Procedure starts with making a side port entry and injecting viscoelastic in the anterior 
chamber. Side port incision is made about 2 o’clock left of entry wound. It is made in clear 
cornea with 15° angled knife or 20 G MVR blade. The side port should measure about 1 mm 
and run parallel to iris plane. After supporting the globe by placing a toothed forceps outside 
limbus opposite to the site of making side port, enter the AC with 15° angled knife or MVR 
blade. 
 
 
Construction of entry wound 
Now make a vertical partial thickness incision at or inside the limbus. It should involve half 
to 2/3
rd
 of corneal / limbal thickness. Now a 3 mm keratome is pushed into the depth of the 
wound and angled forward into the layers of the cornea for about 1.5mm.Direction of 
keratome should be forward and upward following the curve of cornea. Now the direction of 
keratome is changed downward to cut the Descemet's membrane and penetrate into the AC 
Once it has entered the AC, it returns to direction parallel to cornea to extend the entry to the 
required dimensions. 
 
Capsulorrhexis 
Capsulorrhexis, also known as Continuous curved capsulorrhexis (CCC) was developed 
independently in the mid 80s by Gimbel and Neuhann. This single innovation has made 
phacoemulsification a very safe procedure. 
 
 
Techniques:  
Capsulorrhexis can be performed with bent 26 or 27 G needle or capsulorrhexis forces 
(Utrata's forceps). It is remarkably easy with forceps. Fill the AC with viscoelastic. Start 
filling from 6 o’clock and withdraw syringe while injecting. A single perforation is created in 
anterior capsule at 12 o’clock position and extended radially for 2-3 mm to raise a triangular 
flap.  
After a triangular flap has been raised and folded over itself (pushed over the anterior 
capsule), it is rotated clockwise. The needle is repositioned frequently, at least five to six 
times, always on upper surface of the flap and close to end of the previous sector. Certain 
precautions are necessary at this point. 
1. AC should always be full with viscoelastic. 
2. Do not go deep otherwise cortical matter will get disturbed, muffling the details inside the 
AC and making identification of the capsular flap difficult. 
3. Once flap has been raised, the direction of force should be towards the centre. 
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CAPSULORRHEXIS (CCC) 
 
Capsulorrhexis procedure 
Start with the capsulotome (N) in the centre, raise a flap (C), fold it on itself, rotate 360° to complete 
 
Capsulorrhexis with Utrata forceps can be performed after raising a flap with needle as 
described above or an opening can be made in anterior capsule with forceps itself to raise a 
flap. Once the flap has been reversed, it is grasped with forceps and rotated clockwise or 
counter-clockwise. It should be regrasped again and again in more proximal position to 
maintain complete control. Make a 360° rotation and while finishing, bring it from outside to 
inside rather than inside to outside. It is desirable that AC must be reinflated again with 
viscoelastic if chamber collapses as it is likely to happen more with forceps. 
 
Basic rules of capsulorrhexis 
 
1. Always keep AC filled with viscoelastic 
2. Use high magnification 
3. Look for best red reflex 
4. Be patient. Operate slowly and carefully 
5. Repeat capsular grasping several times 
 
Ideal capsulorrhexis is about 5-5.5 mm in size, well centered and circular. This will make 
future maneuvering safe and easy. If capsulorrhexis has extended into the periphery, it is 
better to convert to ECCE, especially for beginners. There is no need to prolapse the nucleus 
into the AC. Ensuring free rotation is however essential. 
 
NUCLEUS MANAGEMENT 
 
DIVIDE AND CONQUER 
 
Divide and conquer nucleotomy incorporates 4 basic steps: 
1. Sculpting until a very thin posterior plate of nucleus, if any remains 
2. Fracturing the nuclear rim and posterior plate of the nucleus and nuclear rim 
3. Fracturing again and breaking away a wedge shaped section of nuclear material for 
emulsification and 
4. Rotating the nucleus for further fracturing and emulsification. 
 
Crater Divide and Conquer (CDC) 
 
Initially, deep central sculpting is done, resulting in a large crater, and leaving a dense 
peripheral rim to fracture into multiple sections. Once this is complete, the nuclear rim is 
fractured, using the bimanual method in which the spatula/chopper and the 
phacoemulsification tip create a counter pressure. The lens is rotated and a second crack is 
made, isolating a pie-shaped section. The nuclear rim is then rotated clockwise, for 
systematic piece-by-piece nucleofractis. The harder the nuclear rim, the smaller the wedge-
shaped sections must be, to allow manageability and to reduce the possibility of tearing the 
posterior capsule. 
 
Usually when performing CDC, especially in dense and brunescent cataracts, rather than 
immediately emulsifying each wedge-shaped section, the nuclear sections are left in place for 
capsular bag distension. Once the fracturing is complete each pie shaped wedge of the 
nuclear rim is brought to the centre of the capsule where phacoemulsification is safely 
accomplished. The ultrasonic turbulence is contained within the lens bag and absorbed by the 
lens, for all but the last one or two nuclear fragments. 
 
Trench Divide and Conquer (TDC) 
 
 
In soft lenses, after making a central trench a central fracture is created, and then the left as 
well as right sides of the lens are divided by fracturing.Many variations of this TDC 
technique exist and are used depending on density of the lens and the surgeon's choice. In 
softer cataracts, the firm nucleus is small and the epinucleus quite soft. The trench should be 
small, central and vertical in these nuclei to leave enough firm nucleus so that the force of 
two instruments can beapplied in nucleofractis. When reaching the 6.0 o’clock epinucleus, 
the phacoemulsification tip, by going deep to the anterior capsule rim, aspirates the 
epinucleus and peripheral cortex because of the adherent tendency of this material. 
 
In soft nuclei, the lens is split by exerting lateral pressure with the phacoemulsification tip 
and spatula at the very center of the lens where the nuclear density is sufficient to resist 
cutting through the tissue with the instruments particularly with the spatula. With the lateral 
pressure at this point in the lens, the splitting usually starts in the posterior pole of the lens 
and extends towards the 6.0 o’clock positions for a complete splitting of the nucleus. The 
phacoemulsification tip is then used to impale the left-and-right-hand sections, and quadrants 
are fractured. 
 
With increasing density of the lens it becomes more difficult to fracture the lens in this way 
unless the trench is made to its full length. This is accomplished by rotating the lens 180 
degrees after sculpting is completed at the 6.0 o’clock position, so that the 12.0 o’clock area 
is now positioned at the 6.0 o’clock. For expediency, it is easier and more efficient to fracture 
the inferior rim with the phacoemulsification tip and spatula positioned just inferior to the 
centre of the lens.  
 
After this initial fracture, which usually extends to one half or three quarters of the diameter 
of the lens, the fracture can be made complete by withdrawing the two instruments back to a 
position just superior to the center of the lens where lateral pressure will often then extend the 
fracture through the nucleus at the 12.00 O' clock position. 
 
After the initial split inferiorly that extends to the centre of the lens or three quarters of the 
diameter, subsequent fracturing can be accomplished without the first fracture complete to 
the 12.0 o’clock position. The direction of the phacoemulsification tip is angled to the left 
and with a little more sculpting centrally the tip burrows deeply into the nucleus of the left 
hemisection. While the hemisection is stabilized with a spatula and aspiration, but no 
ultrasonic power the phacoemulsification tip is pushed and rotated clockwise to break off a 
pie-shaped inferior section of the lens. In softer nuclei this usually will break as a quarter 
section. 
 
In more firm nuclei one can try to break away a smaller section, usually about one third of the 
hemisection. After this section is pulled to the centre by aspiration, it is emulsified. 
 
Then, either another section can be similarly broken on the left hand side or the spatula can 
rotate the remaining three quarters of the nucleus counter clockwise, so that the 
phacoemulsification tip can then burrow into the right hemisection and break away one third 
or one half of this section while the remainder is stabilized with the spatula. 
 
After fracturing is complete, the phacoemulsification setting is switched to the pulse mode to 
enhance holdability of the nuclear fragments to the phacoemulsification tip. The second 
instrument is then used to elevate the central apex of each quadrant and the phaco tip is used 
to deeply engage the nuclear fragment. Once occlusion has occurred the segment is brought 
into the middle of the epinuclear shell to be emulsified. The remaining quadrants are rotated 
and sequentially emulsified in a similar manner, leaving an intact epinuclear shell. 
 
Four Quadrant divide and conquer 
Beginner should start with sculpting. This is preferably done with 30° or 45° needle. Setting 
of machine should be as follows. 
Vacuum : 20-40 mm Hg 
Flow : 18-20CC/ minute 
U/S power : 70%  
After stabilizing the nucleus with spatula/ chopper introduced through side port, start making 
a groove on the nucleus from 12 to 6 o’clock. Press the foot pedal to position 3 and move the 
handpiece toward 6 o’clock edge of the capsulorrhexis. Never try to reach to the edge of the 
nucleus. Once at 6 o’clock, comeback to position 2 on foot pedal. The groove should be one 
phaco-tip wide and depth should be about 80%. Depth can be judged by depth of two sides of 
the groove and presence of red reflex obtained through the remaining nucleus. In soft 
nucleus, trench should be narrow deep and localized to central 2/3 whereas in hard cataract 
trench should be wide and reach further toward the edge of nucleus. Now, engaging the 
spatula at the end of tunnel rotate the nucleus by 90°. 
 
Same procedure is repeated for each half. In between, that is, when rotating the nucleus, the 
foot pedal should be at position 1(irrigation only). After required depth has been achieved, 
stage is set for cracking the nucleus. With foot pedal at position 1, place the phaco-tip on 
right side and spatula or chopper on other side and separate the piece with lateral gentle force. 
It is very important that both instruments should be placed deep in the groove. A beginner 
can use two spatula/ choppers to divide the nucleus after filling the eye with viscoelastic. The 
direction of force should be horizontal with no vertical component. The procedure is then 
repeated to completely separate the four quadrants. At this stage, ensure the crack is complete 
posteriorly and all four quadrants are separated from each other. 
 
Change the machine parameters as follows: 
Vacuum: 150-200 cc 
Flow: 20-24 cc/ minute 
U/s power: 20% 
Engage one piece at its depth, bring it forward and emulsify in iris plane. 
Repeat same procedure for other 3 quadrants. 
 
Phaco Chop 
 
This technique is based on a principle that adopts the physics of splitting wood. A chopping 
instrument (thehatchet) is used to split the nucleus (the log) resting against the 
phacoemulsification tip (the chopping block). This permits the nucleus to be fractured along 
its longitudinal fibres using appositional forces rather than the parallel forces used by Gimbel. 
Every motion pulls the nucleus in towards the middle of the capsular bag, moving it out of 
the capsular fornix. 
After completing capsulorrhexis and the hydrodissection, the phacoemulsification tip is 
placed in the eye burying it in the nucleus as far superiorly as possible. The nucleus is held 
firmly preventing it from moving superiorly as the chop is performed. 
 
Next, an instrument, that is a chopper is placed in the eye through the side port incision and 
pushed down into the nucleus as far as the capsulotomy would allow. It is then pulled up 
towards the phacoemulsification tip, ripping a narrow groove in the nucleus as it cuts its way 
towards the chopping block.  
 
As the second instrument (chopper) approaches the phacoemulsification tip the two 
instruments move gently apart, the chopper to the left and the phaco tip to the right 
effectively chopping the nucleus in two pieces. The operation continues, with the nucleus 
being rotated 90 degrees orienting the original chops horizontally and then the steps were 
repeated on the inferior half of the nucleus. The phacoemulsification tip is buried in the 
nucleus half just inside the original chop, the chopper is placed inferiorly and pulled up 
towards the phacotip, chopping the inferior nucleus half into quarters. After another rotation, 
the second nucleus half is also chopped into two. The four quarters were now emulsified. 
 
 
Stop and Chop 
 
Koch and Katzen, modified the phaco-chop technique to provide space for tissue separation, 
nucleus manipulation, and aid ease of removal. Without tissue removal the nuclear segments 
could fall back together after each chop, reassembling like an intraocular jigsaw puzzle. 
Hence a crater or a trench is made first and then one stops and then chopping is performed. 
 
Fig.9  STOP& CHOP TECHNIQUE 
 
 
Initial trench 
 
 
Rotation & separation 
ofnuclear fragment 
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half 
 
 
 
Phacoemulsification of 
nuclear pieces 
Stop & Chop technique 
G - Golden Ring; C - Cortex; F - Sharp chopper ; P - Phaco tip; H - Nuclear half; 
1,2 - Breaking nucleus in two halves; 3 - Chopping the nuclear half 
ASPIRATION AND IRRIGATION 
 
The instruments used for irrigation aspiration can be automated or manual. Automated 
systems of I/A have the following advantages. 
 
1. Vitreous is pushed back thus ensuring safety of posterior capsule. 
2. Less chance of endothelial damage due to well maintained AC. 
3. Easier I/A because of open and accessible capsular fornices. 
 
Manual I/A however, has greater flexibility, greater surgeon control and is easily learnt. 
Aspiration following phacoemulsification is different from ECCE. The amount of cortex after 
the former is much less, it is well hydrated and thus easily aspirated. 
 
Further, there are no loose capsular tags and capsular fornices are well opened due to well 
maintained AC. However, it is difficult to remove the cortical matter from 12 o’clock region 
because approachability is limited due to CCC and small incision, especially when it is clear 
corneal. 
The stages of adequate cortical clean up include. 
1. Seeking occlusion 
2. Grasping which implies a greater occlusion by activating suction and 
3. Traction to strip the cortical tissue. 
There are several difficulties in aspirating subincisional cortex. 
 
 
Reasons for difficulty during aspiration of subincisional cortex with the tunnel incision 
  Long pathway of the tip inside the tunnel 
 Difficult verticalization of the tip as well as access to the capsular equator 
  Increase in fluid leakage and decrease of chamber depth due to divarication of incision  
lips 
  Small rhexis 
  Distally decentralized rhexis 
 Possible miosis 
 Corneal folds 
 
The methods described to aspirate the subincisional cortex are the following: 
1. Post IOL implantation, dialing the IOL loosens cortex making aspiration easier. 
2. Using a 26 G 'J' shaped cannula 
3. Using a 30 G cannula through side port, i.e. suck and spit method. The entire lens matter is 
engaged using the cannula and pulled towards 6 o’clock and released into the anterior 
chamber. This is then aspirated using Simcoe I/A cannula or a syringe filled with 0.25 cc 
BSS. 
4. 6 o’clock approach - A stab incision is given at 6o’clock and 30g cannula isused through 
the side port. 
Vacuuming and polishing can also be done with I/A tip with suction kept at the minimum 
(25-30mmHg). 
 
INTRAOCULAR LENS IMPLANTATION 
 
The IOLs which can be used after phacoemulsification are single piece PMMAIOLs or 
foldable IOLs. The rigid IOLs used in phaco surgery have an optic diameter of 5.5mm or less 
so that only one suture is required to close the wound. Foldable IOLs can be made of soft 
acrylic and hydrogels or silicon ematerial. The design can be either three piece lenses or 
single piece or platehaptic design. Presently, three piece lenses are used and plate haptic 
design is used for toric IOLs to correct astigmatism of < 3D. 
 
The insertion devices can be either a specially designed forceps or injector systems. The 
folding techniques are based on horizontal principle which allows a one step implantation or 
anvertical principlewhich requires a 2 step implantation. Silicone lenses cause less 
endothelial and uveal damage and are autoclavable. However, they may be associated with 
greater decentration and posterior capsule opacification (PCO) or after cataract as compared 
to acrylic lenses. Further, these cannot be implanted is eyes with silicone oil or where future 
vitreoretinal procedures are anticipated. As of now, the acrylic lenses provide the best visual 
performance and least amount of PCO. 
 
PHACOEMULSIFICATION FOR A BEGINNER 
Phacoemulsification has a long learning curve. Failures at every stage are bound to come. But 
at sometimes this must be learned and mastered. As this is technique for present and future 
and without phacoemulsification professional survival of cataract surgeon may be in danger. 
Here outlined are a few steps with Phacoemulsification procedure: 
 1. Be well conversant with use of microscope including use of foot control 
2. Know your machine well 
3. Select a case with patient age about 50-60 years, well dilated pupil, Grade-II / III nucleus 
hardness, and preferably right eye for right handed surgeon 
4.Make a limbal bevelled incision at 12 o’clock or superotemporal site. So if need arises it 
may be extended 
5. Ensure nucleus rotation by good hydro dissection 
6. Perform a capsulorrhexis 
Any failure at stage 4 (premature entry with frequent iris in section) and 5 &6 consider 
converting to ECCE. 
7. Start with sculpting and four quadrant divide and conquer 
8. Ensure first vertical crack is complete vertically and more important posteriorly 
Phacoemulsification is an ordinary human effort. If others can do it so can you. By 
determination and perseverance you will definitely be able to master it 
What to expect with cataract surgery 
Before surgery: 
 
An ophthalmologist will measure affected eye to set the proper focusing power for our IOL. 
Also, the doctor will ask about any medicines currently used by the patient. Some of these 
medicines may have to be stopped before surgery. The prescribed eye drops are to start 
before surgery. These medicines help prevent infection and reduce swelling during and after 
surgery. 
The day of surgery: 
Cataract removal surgery may be done in an outpatient surgery center or in a hospital.  
 The eye will be numbed with LA eye drops or with an injection around the eye.  
 The patient will be awake during surgery seeing light and movement during the 
procedure, but not able to see what the doctor is doing to the eye. 
 Surgeon will enter into the eye through tiny incisions (cuts, created by laser or a 
blade) near the edge of the cornea.  
 The surgeon uses these incisions to reach the lens using very small instruments and 
will break up the lens with the cataract and remove it by motorized suction apparatus.  
Then the IOL is inserted into place. 
 Usually surgeon will not need to stitch the incisions closed. These “self sealing” 
incisions eventually will close by themselves over time. A shield will be placed over 
the eye to protect it while it heals from surgery. 
 The patient will be rested post-operatively in a recovery area for about 15–30 minutes. 
Then will be ready to go home. 
POST SURGICAL RECOVERY: 
Days or weeks after surgery: 
 The patient must use eye drops after surgery, following the surgeon’s directions for 
using these drops 
 Should avoid getting soap or water directly into the eye 
 Do not rub or press on the eye. An ophthalmologist may ask to wear eyeglasses or a 
shield to protect the eye 
 The patient has to wear a protective eye shield while sleeping 
 The ophthalmologist will talk about how active one can be soon after surgery. He/She 
will tell when one can safely exercise, drive or do other activities again 
 
IOL Implants: Lens Replacement after Cataracts 
An intraocular lens (or IOL) is a tiny, artificial lens for the eye. It replaces the eye’s natural 
lens that is removed during cataract surgery. The lens refracts light rays that enter the eye, 
helping you to see. Our lens should be clear. But if we have a cataract, our lens has become 
cloudy. Things look blurry, hazy or less colourful with a cataract. Cataract surgery removes 
this cloudy lens and replaces it with a clear IOL to improve our vision. 
IOLs come in different focusing powers, just like prescription eyeglasses or contact lenses. 
An ophthalmologist will measure the length of the eye and the curve of the cornea. These 
measurements are used to set the IOLs focusing power. 
 
INTRAOCULAR LENSES (IOLs) 
There are several choices of intraocular lenses used in cataract surgery – a standard 
monofocal intraocular lens (IOL), a toric IOL, a multifocal IOL or an accommodating lens: 
A standard monofocal IOL is a fixed lens (it doesn't move) that is designed to deliver 
improved vision at one distance (usually far). The potential drawback is that after surgery, we 
may need to wear glasses for near and intermediate vision, even if, didn't wear glasses before 
surgery. 
A toric IOL adjusts for individual astigmatisms and may minimize the need for distance 
vision glasses after surgery. The TRULIGN Toric IOL corrects the cataracts and  astigmatism. 
It also gives a broader range of vision, from arm's length to distance. 
A multifocal IOL is designed to deliver improved vision for distance and near. However, 
some patients may experience some halos and glare when driving at night, and some patients 
have difficulty adjusting to their new vision. 
An accommodating IOL is designed to "flex" or "accommodate" using the eyes natural 
muscles to focus on subjects at various distances, delivering a fuller, more natural range of 
vision. Crystalens AO Lens was the first FDA-approved accommodating lens available in the 
United States. Crystalens is an artificial lens implant that, unlike a standard IOL, can treat 
both a person's cataracts and presbyopia—loss of near and intermediate vision. We probably 
noticed in our forties that we started to lose some of our up-close vision and had to start 
wearing reading glasses. Crystalens not only treats the cataracts but provides a more natural 
range of vision. It does so by recreating accommodation similar to our eye's natural lens. The 
unique Crystalens is designed to allow to enjoy most activities, including: reading a book, 
working on the computer, and driving a car. 
 
Prevention of Cataracts 
 
To reduce the risk of developing cataracts: 
 Protect eyes from UVB rays by wearing sunglasses outside 
 Have regular eye exams 
 Stop smoking 
 Eat fruits and vegetables that contain antioxidants 
 Maintain a healthy weight 
 Keep diabetes and other medical conditions in check 
 
Latest trends 
Another sophisticated piece of technology that is even newer is called ‘Intraoperative 
wavefront aberrometry’. Once the cataract has been removed, a device attached to a 
microscope measures the total refractive error of the eye. "This essentially allows us to more 
accurately ensure we're implanting the appropriate lens power for the eye, and increases our 
chances of hitting our target. This has been especially helpful for people who have had 
previous laser vision correction, such as LASIK or PRK, where the usual preoperative 
measurements and calculations are not as accurate. 
The laser and ‘intraoperative wavefront aberrometry’ have also improved accuracy when 
eliminating astigmatism that causes images to appear distorted or blurry. During a cataract 
procedure, the surgeon can correct minor astigmatism by making carefully placed incisions in 
the cornea to normalize its curvature. For more severe astigmatism, the surgeon can insert 
special lenses into the eye, called toric intraocular lenses. "This allows a person to see more 
clearly at a distance with less dependency on glasses, though reading glasses are generally 
still required for near vision". 
Actually, all standard replacement lenses require us to use reading glasses after surgery, 
regardless of whether have astigmatism. However, we can invest in special multifocal 
replacement lenses, similar to bifocal eye glasses, that correct both distance and close-up 
vision. Most people with extensive astigmatism aren't candidates for these lenses. 
 
Hope on the Horizon: Stem Cells Treating Cataracts 
Outside of first world countries like the U.S., surgery isn’t always an accessible option. There 
is however hope on the horizon. New cataract treatments will be less invasive; simplified 
surgical methods and cataract fighting eye drops could change the landscape for cataracts 
sufferers of the future. 
Stem cells, which have been studied in the treatment of a variety of ailments, are also being 
researched in the cure of ocular issues. Scientists from China and the U.S., working in 
collaboration with one another, recently performed surgeries to remove the cloudy cataracts 
from the eyes of monkeys and rabbits. The lens capsule, however, was kept intact after the 
procedure, along with epithelial stem cells. In the experiment these stem cells went on to 
regenerate the missing lens over the span of several months and vision subsequently 
increased. The consistently successful results produced in the animals allowed the test to be 
expanded to several human children, where the results were once again positive. 
Additional testing needs to be done, as it is thought that for adults, stem cell treatment for 
cataracts could be more difficult as they have less responsive epithelial stem cells than 
younger patients. For children however, this innovation is especially exciting because they 
shouldn’t need those subsequent surgeries that are currently standard with cataracts treatment. 
Treatment of cataracts can occur as a result of other eye diseases, they mostly develop 
naturally with age. In fact, by age sixty five, many people will develop a cataract. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Literature Review 
II. LITERATURE REVIEW 
 
CATARACT: 
Cataract is the single-largest factor for blindness in India, accounting for nearly 63 % of the 
total burden of vision impairment in the country.  
  
It is reported that after cataract (62.7 per cent), in descending order of prevalence, the 
causes of blindness were uncorrected refractive error (19.7 per cent), glaucoma (5.8) per 
cent, posterior segment disorder (4.7 per cent) and corneal blindness (1 per cent).According 
to a group of ophthalmologists, who were speaking to the media at Rajendra Prasad Eye 
(RP) Centre for Ophthalmic Sciences at the AIIMS, India currently has the highest numbers 
of blind and visually impaired people.  
 
"In India, there are nearly 0.8 crore blind and 5.4 crore visually impaired. Nearly 80-90 per 
cent blindness is avoidable and more than 90 per cent of it is seen in people aged 50 years 
and above," said the Chief of Rajendra Prasad (RP) Eye Centre for Ophthalmic Sciences at 
All India Institute of Medical Sciences (AIIMS), New Delhi. 
 
Stating that patients were ignorant about various causes which damaged optic nerves a 
Professor of Ophthalmology at AIIMS, said that tobacco, betel nut and lime also caused 
damage to eyes, without the patients having any idea. Some medicaments, esp., Steroids are 
also a reason behind blindness. This is becoming common and nearly 20 per cent of 
children with blindness is because of the steroids. However, with the advancement in age, 
chances of people going blind due to steroids become less. The RP Centre is also 
conducting a "National Blindness Survey 2015-18" with a sample size of 90,000 people, 
using Rapid Assessment of Avoidable Blindness (RAAB) method. 
 
Blindness survey 2015-18 is scheduled to be completed in 2018. Doctors said that the 
survey would provide the most reliable representative current estimates of blindness and 
visual impairment among those aged 50 and above. It will also generate, for the first time, 
the burden of diabetic retinopathy and sight threatening diabetic retinopathy in a 
representative community sample. 
At the turn of the century, WHO and the International Agency for Prevention of Blindness 
launched the Vision 2020: the right to sight initiative (Foster A. 2000). The most recent 
estimates from WHO reveal that 47.8% of global blindness is due to cataract and in South 
Asia region which includes India, 51% of blindness is due to cataract (World Health 
Organization, 1997). Since cataract is a major cause of avoidable blindness in the developing 
countries, the key to the success of the Global Vision 2020: the right to sight initiative is a 
special effort to tackle cataract blindness (Foster A. 2001). Cataract surgery has been viewed 
as one of the most cost-effective health interventions with a cost of disability-adjusted life 
years saved of US $ 20-40. 
 
Cataract surgical rate is a quantifiable measure of the delivery of cataract services in a 
country (Limburg H et al., 1997). It is thus a good indicator of how well a country is 
organizing its efforts in tackling cataract-related blindness. There has been a substantial 
increase in Cataract surgical rate (CSR) in India especially after the inception of the World 
Bank-supported Cataract Blindness Control Project (Jose R and Bachani D. 
1995). Professional interest and technological upgradation of skills and the availability of 
affordable equipment and intraocular lenses have all fuelled the increase in cataract surgery 
in India. A CSR of 3000 was targeted under Vision 2020: the right to sight, for India, by the 
year 2000. Current trends show that this target has been achieved, but still there are regional 
disparities across the country. The CSR for the year 2002-03 ranges from a high of 8440 per 
million populations to a low of 130 per million population(Jose R and Bachani D. 2003).  
 
According to Jose R and Bachani D. (2003) most of the bigger states in the country have 
already achieved a CSR of > 4000 per million population. The states of Gujarat (8440), 
Puducherry (7440), Tamil Nadu (5920) Andhra Pradesh (5260), Delhi (5090), Punjab (4950), 
Maharashtra (4840), Karnataka (4560) and Haryana (4180) have already gone past the 
recommended norm for Vision 2020: the right to sight. In view of this encourageing 
performance, it is very likely that the entire country can achieve a CSR of 6000 + per million 
population by 2020. This increased performance will reduce the prevalence of blindness and 
severe visual impairment in the country as half the blindness in India is attributable to 
cataract (Murthy GV et al., 2005). 
In epidemiologic parlance, a ′true′ rate is a proportion and is defined as the presence or 
absence of a characteristic in a group of people among people who are at risk of developing 
the particular disease during a specific time period. Therefore the denominator should 
comprise only individuals in the population who are at risk of developing the disease. In such 
a case, the denominator of the general population is not appropriate for defining CSR as the 
younger population would not be at risk of age-related cataract. It is therefore recommended 
that since most blinding cataract occurs after the age of 50 years, the denominator for CSR 
should consist only of the 50+ population. 
 
If CSR per million 50+ population is considered, then by 2020, elimination of avoidable 
blindness due to cataract does not seem to be possible. In addition, if the incidence of new 
cataract blind individuals is added to the prevalent cases, it appears that India would be a long 
way off from eliminating avoidable blindness due to cataract by 2020. 
 
If 30% continue to remain blind after cataract surgery, then the CSR/ million 50+ will need to 
increase by a third at different time periods. The situation gets compounded further if in 
addition to the above parameters, sight restoration is considered, and only 60% of all cataract 
surgeries are done on the blind, then the elimination of avoidable blindness due to cataract 
appears to be a dream in India unless a significant proportion of the 50+ have been 
′prevented′ from going blind by operating at better visual acuity and by ensuring a better 
postoperative outcome. 
 
Cataract surgical coverage (CSC) is an efficient indicator for planning as it provides 
information on what proportion of those needing surgery have been covered and therefore is a 
good indicator of the work remaining. However, CSC needs population-based surveys to 
provide information which is not easily available as against CSR which is most readily 
available. It is difficult to say if there is any over-reporting in cataract surgery when 
information is compiled at the national level. It is important to look at what proportion of 
cataract surgeries actually lead to a decrease in blind people (presenting vision < 20/200 in 
the better eye) after surgery compared to their preoperative status. Other researchers also 
consider that monitoring sight restoration rate is very important for planning at the national 
level (Limburg H  et al., 1996) and (Lewallen S &Courtright P 2002). This is important 
because the Vision 2020:the right to sight approach is targeted towards the bilaterally blind. 
Surgeries on people who have a presenting vision better than 20/200, surgeries on the second 
eyes, and surgeries on the unilaterally blind would not help in restoring vision though they 
have a role in preventing future blindness and should not be accounted for when monitoring 
progress towards the goal of elimination of avoidable blindness due to cataract. For the 
immediate future when a significant proportion of the 50+ are blind, the first priority should 
be given to restoring vision to those already blind.  
 
Therefore, it would be more meaningful to monitor sight restoration in addition to CSR/ 
million population and CSR/ million 50+ population to monitor progress towards Vision 
2020. Recent evidence in India suggests that the visual outcomes after cataract surgery are 
not very good in some regions wherein the operated people continue to remain blind after 
surgery. Poor visual outcome has been reported in 15-25% of eyes following cataract surgery 
 (Limburg H et al., 1999). A study in southern India reported poor or very poor visual 
outcome after cataract surgery in 51.9% of the operated eyes (Dandona L et al., 1999). 
 
Another study in northern India showed that one-third of the eyes which had a preoperative 
vision of less than 20/200 continued to have vision less than 20/200 with best correction after 
cataract surgery (Murthy GV et al., 2001). A study in Mysore, India, demonstrated that more 
than one-third were blind in the operated eye (Singh AJ et al., 2000). Improving the quality 
of surgery is a major input that needs to be emphasized now that the quantity of surgery has 
been increased. This along with improved Sight Restoration Rate per Year(SRR) will be 
more effective in eliminating cataract blindness. 
 
The projections have been made using a simple dynamic model using Microsoft Excel 
software considering assumptions as mentioned. If the assumptions change, then the 
projections would also change. Age-specific mortality has been used to project future 
population in different age cohorts and it is assumed that most of the surgical patterns and 
outcomes will remain constant to a large extent. 
 
Most literature concentrates on the prevalence of cataract blindness in projecting future 
trends. However it is also important to consider the newly blinded individuals (incident cases 
of cataract blindness) as they would also need to be treated. The backlog of cataract blindness 
can be tackled effectively only if the incident cases are also accounted for. Unfortunately, 
estimates of incidence of cataract blindness are difficult to obtain because of the long 
duration of the disease and the uncertainty of the pace of progression to blindness in cataract. 
Conventionally, it has been stated that the incidence of cataract blindness is 20% of 
prevalence (Foster A. 1993) and (Duerksen R et al., 2003). 
 
Studies in South Africa and India have documented that the incidence ranges between 23-
30% of prevalence (BhattacharjeeJ  et al., 1996).  Assuming that the incidence of newly 
blinded cataract is 20%, it appears that the present number of cataract surgeries need to be 
scaled up significantly if the elimination of avoidable cataract blindness is to be a reality by 
2020. It needs to be emphasized that outcome measures like CSR and CSR 50+, by 
themselves are inadequate to describe the benefit to the operated individuals and their quality 
of life. More widespread use of indicators like SRR and developing sensitive indicators for 
assessment of visual function after surgery should be effectively used in the future. At the 
same time, other causes of avoidable blindness need to be given adequate attention.  
 
As may be evident about 10% of the cataract surgeries are done on patients <50 years of age 
and this trend may increase with increased incidence of diabetes, increase in posterior 
subcapsular cataract and improved phacoemulsification surgery penetration in India. More 
number of people would be operated upon sooner than they are today. Data from three 
surveys conducted in India show this clearly. Different methodologies were used in these 
surveys, and any inappropriate estimation in these surveys could affect the comparability of 
their findings in this study. The CSR and SRR suffer from the fact that they are based on 
reported figures whose validity or accuracy cannot be scrutinized. Some program managers 
suggest that the incidence of cataract in India has been overestimated (Thomas R and 
Muliyil J 1998). If this is true, it may be easier to achieve the targets for elimination of 
avoidable blindness due to cataract in India as would improve visual outcomes after cataract 
surgery which is eminently feasible in the immediate future. 
Although modern cataract surgery is extremely safe, postoperative endophthalmitis remains 
the most feared complication, and cystoid macular edema (CME) continues to be the most 
common cause of vision loss after routine cataract procedure. In 2013, discussion continued 
about the role of intracameral versus topical antibiotics for infection prophylaxis, and cataract 
surgeons had several new options for use in controlling inflammation after cataract surgery. 
When it comes to the debate about endophthalmitis prophylaxis Regimens, a key event that 
year was the publication of a study by Shorstein et al.,(2013)  from Kaiser Permanente 
Northern California that showed the rate of postoperative infections decreased after the 
institution of intracameral antibiotic use. 
The intracameral use of antibiotics following cataract surgery significantly reduces the risk of 
postoperative endophthalmitis when compared to the pre-or postoperative use of topical 
antibiotics. The prophylactic use of this therapeutic Regimen is a current practice in Europe 
and in a large number of countries around the world. It is not routinely followed in the US 
because no commercial antibiotic for intracameral use has been approved by the Food and 
Drug Administration. With this update on the topic, the Brazilian Society for Cataract and 
Refractive Surgery intends to show the positive impact of the intracameral use of antibiotics 
on reducing the rates of endophthalmitis following cataract surgery and highlights evidence 
of good outcomes that reinforce the safety and efficacy of this prophylactic therapeutic 
Regimen. 
Herrinton et al.,(2016) performed a longitudinal, observational, and controlled cohort study 
of approximately 315,000 phacoemulsification procedures to identify which prophylactic 
Regimen was the most effective. They compared the intracameral use of antibiotics 
(cefuroxime or moxifloxacin) to the topical use of antibiotics (gatifloxacin, ofloxacin, 
polymyxin-trimethoprim, moxifloxacin, neomycin, gentamicin, or tobramycin). The authors 
found 215 cases of endophthalmitis (0.07% or 0.7 per 1,000 cases). The intracameral use of 
antibiotics was more effective than the topical use of a single antibiotic [OR: 0.58; 
confidence interval (CI): 0.38–0.91]. The combination of intracameral antibiotics and topical 
applications of gatifloxacin or moxifloxacin was not more effective than the intracameral use 
alone (OR: 1.63; CI: 0.48–5.47). When compared to the topical use of other antibiotics, 
topical gatifloxacin reduced the risk of endophthalmitis by 42%; neomycin, gentamicin, and 
tobramycin were less effective (OR: 1.97; CI: 1.17–3.31). The risk of endophthalmitis in 
patients not administered with intracameral antibiotics in this study was lower than that in 
other studies (0.044% risk of endophthalmitis in the intracameral group and 0.070% risk in 
the topical group). These data were consistent with those of the ESCRS study (0.05% risk of 
endophthalmitis in the intracameral group and 0.35% risk in the control group) ESCRS 
(2007). The authors concluded that the intracameral use of antibiotics was more effective for 
preventing endophthalmitis following cataract surgery than the topical use of antibiotics 
alone (Arbisser LB. 2008). 
 
The topical use of antibiotics did not render the intracameral Regimen any more effective. 
The authors found no convincing evidence of a difference in efficacy between intracameral 
moxifloxacin and cefuroxime. In this study, moxifloxacin was used directly and concentrated 
or diluted in equal parts of balanced saline solution to obtain a concentration of 250 µg per 
0.1 ml. The authors reported the intracameral application of cefuroxime in 13 eyes (11 
patients), with an error of formulation of 9 mg, which resulted in acute macular edema that 
was resolved within 1 week with no further complications(Yoeruek E. et al., 2008). That was 
the first study to report an association between the intracameral use of cefuroxime and 
adverse effects. Increased resistance to fluoroquinolones may support the use of cefuroxime, 
particularly in patients exposed to fluoroquinolones in the past. The intracameral injection of 
any antibiotics may be less subject to the occurrence of resistance as the antibiotics are 
administered as a single concentrated dose in a relatively confined space in contrast to the 
topical use of antibiotics, which include repeated and less effective low doses of the drug 
(Arbisser LB. 2008).Vancomycin has also been used in intracameral injections to prevent 
infection and has been found to be effective against gram-positive bacteria. However, 
concerns over resistance have limited its use to approximately 1% of patients who are allergic 
both to penicillin/cephalosporins and fluoroquinolones. In their conclusion, the authors 
recommended the intracameral injection of cefuroxime or moxifloxacin in all phaco-
emulsification surgeries. The use of a topicalagent alone is less effective and is also subject to 
errors in prescription and a lack of patient compliance. Topical aminoglycoside antibiotics 
are less effective in preventing endophthalmitis (Hui M.et al., 2011). 
 
Based on the results of approximately 3 million cataract surgeries in the US annually, the 
adoption of the intracameral use of antibiotics may potentially save more than 2,000 eyes per 
year from the negative impact of postoperative endophthalmitis (Javitt JC 2016). 
 
The intracameral use of antibiotics to prevent infection following cataract surgery and other 
intraocular surgeries began in 2002(Montan PG etal., 2002). The multicenter, prospective, 
randomized study by  ESCRS (2007) which  evaluated  the  prophylactic  use of  intracameral  
versus topical antibiotics, considered 16,000 patients and found 4.92 times more risk of 
endophthalmitis with the topical use of antibiotics. This result made the intracameral use of 
antibiotics widespread in Europe despite the lack of an approved intracameral antibiotic 
formulation. Later, the commercial formulation of cefuroxime for intraocular use was 
accepted across the European Union. It is important to note that the fixed price of cefuroxime 
was substantially lower than that of antibiotic eye drops(Javitt JC 2016). 
 
The main limitation of the intracameral use of antibiotics in the US is the lack of approval by 
FDA of a commercial antibiotic for intracameral use. American ophthalmologists are 
dissuaded from the intracameral use of antibiotics based on the risk of legal and financial 
consequences because the product is not approved for this use and would therefore need to be 
used off-label. As previously mentioned, the preparation of the product in the operating room 
has many risks. In the US, despite the existence of pharmacies licensed to supply sterile 
products, they are requested only for special patients. Recently, FDA inspected 28 
pharmacies authorized to produce sterile medications and identified violations in each one of 
them (USFDA2013). Javitt JC (2016) also reported the following barriers: a) no commercial 
sponsor has presented FDA with a new drug application, b) minimum financial return is 
expected, and c) there is a need for guidelines to regulate controlled safety and efficacy 
studies of the actual drug that the manufacturer plans to sell.  
TOPICAL Vs. INTRACAMERAL ANTIBIOTICS: 
Antibiotics  
Antibiotics are drugs, either of synthetic or natural origin, that are used to treat infections 
caused by bacteria and other microorganisms. The discovery of antibiotics beginning with 
sulfonamides and β-lactams in the mid-20th century enabled rapid treatment of bacterial 
infections that had previously proven to be fatal. Between 1930 and 1970 in the “golden age” 
of antibiotic research, many classes of antibiotics that are still in use today were discovered. 
Since then, overuse and misuse of antibiotics has resulted in the emergence of antibiotic 
resistant microorganisms and has fuelled the continuance of antibiotic development. 
Increasingly, antibiotic resistance has become a major threat to public health. The various 
classes of antibiotics are active against different types of bacteria and can have either 
intracellular or extracellular targets.  
Bacteria are generally classified into one of two groups based on the structural differences in 
their cell walls: Gram-positive or Gram-negative. Gram-positive bacteria have cell walls that 
are composed of a single peptidoglycan layer attached to an inner cytoplasmic membrane. 
Gram-positive bacteria retain crystal violet dye in the Gram staining protocol. In contrast, 
Gram-negative bacteria do not retain the dye. Gram-negative bacteria have an additional, 
second outer membrane, which acts as a permeability barrier and convers the peptidoglycan 
of the cell wall. Due to the additional cell membrane, it is more difficult for antibiotics to 
penetrate Gram-negative bacteria. Thus in many cases, classes of drugs that are useful against 
Gram-negative organisms are also useful against Gram-positive, but not vice versa. Narrow 
spectrum agents are active against only a specific type of bacteria, while broad spectrum 
agents are active against many different bacteria, often both Gram-positive and Gram-
negative organisms.  
Some antibiotics have cellular targets that do not require the antibiotic to fully transverse into 
the bacterial cell or cytoplasm, such as vancomycin that targets the peptidoglycan of Gram-
positive bacteria, while others have cytoplasmic targets, such as sulfonamides and 
Fluoroquinolones. The activity of an antibiotic is commonly characterized by minimum 
inhibitory concentration (MIC). MIC is ascertained by a standard growth assay in which the 
concentration of the drug required to block visible growth of a bacterial population is 
determined. Lower MICs correspond to increased activity. MIC is a measure of bacterial 
growth and does not differentiate bactericidal and bacteriostatic antibiotics. Percent DNA 
cleavage is a measure of activity that is commonly used to evaluate activity of topoisomerase 
inhibitors, such as fluoroquinolone antibiotics. Higher percent DNA cleavage corresponds to 
increased activity. In the present work, both MIC and percent DNA cleavage are used as 
measures of fluoroquinolone-class antibiotic activity. Drug resistant microorganisms are 
responsible for an increasing number of community-acquired and hospital-acquired 
infections, including those from Staphylococcus aereus, Pseudomonas aureginosa, 
Streptococcus pneumoniae, and Mycobacterium tuberculosis. These drug resistant 
microorganisms display reduced or nonexistent susceptibility to antibiotic drugs, thus 
allowing the infections to persist in patients and increase the numbers of fatalities. When first 
choice antibiotics do not work to treat an infection, a second or third, often more toxic “drug 
of last resort” is administered in an attempt to treat the drug resistant infection. Consequently, 
usage restrictions have been placed on these drugs of last resort in order to decrease the 
chance of selecting for microorganisms that are resistant to these agents.  
There are three general mechanisms of resistance that are common to many classes of 
antibiotics: chemical modification or breakdown of the antibiotic, failure of penetration 
including efflux transporters, or specific changes to the target. Common examples of 
chemical modification and antibiotic breakdown are the enzymatic addition of acyl functional 
groups to the aminoglycoside antibiotics, and the destruction of β- lactam antibiotics by β-
lactamases. Failure of the drug to penetrate the microorganism can occur by several methods: 
mutation or down regulation of the drug transporters that take in the drug, upregulation of 
efflux transports that actively pump the drug out of the bacterium once it is inside, or 
alteration of the cell wall composition so the drug can no longer penetrate the bacterium.  
 
Antibiotic targets can be altered through changes in expression levels or through spontaneous 
mutation in the genes encoding the target that cause alterations in target structure and prevent 
the antibiotic from interacting with the target. Alteration of the target through mutation is one 
of the main mechanisms of resistance to Fluoroquinolones, the class of antibiotics that is the 
focus of this dissertation. Each of these mechanisms of resistance prevents the antibiotic from 
effectively acting on its bacterial target. Resistance can exist, be selected for, and be 
promoted by using antibiotics. In a large population of bacteria, it is likely that there are 
several cells that are inherently resistant to one or more antibiotic agents due to the genetic 
variation within the population. When an antibiotic is applied to the population of bacteria, all 
the susceptible cells die, leaving behind the resistant bacteria. The remaining bacteria can 
then reproduce to produce a large colony of drug resistant microorganisms over a short period 
of time. 
 
Current practice methods are unclear as to the most safe and effective prophylactic 
pharmacotherapy and method of delivery to reduce postoperative endophthalmitis 
occurrence. In a recent meta analysis it is stated that Intracameral antibiotics (cefuroxime and 
moxifloxacin) reduced endophthalmitis rates compared with controls with minimal or no 
toxicity events at standard doses. Additionally, intracameral antibiotics alone may be as 
effective as intracameral plus topical antibiotics (Bowen R.C. et al., 2018). 
 
 
 
Fluoroquinolone Antibiotics: 
Fluoroquinolones are a class of broad spectrum antibiotics. Clinically, fluoroquinolone class 
agents have been used to treat a variety of infections due to their broad spectrum activity 
against Gram-positive and Gram-negative bacteria: respiratory infections, sexually 
transmitted diseases, and enteric infections among others. Fluoroquinolones are structurally 
based on nalidixic acid, an antibiotic of synthetic origin that was discovered in 1962 . At low 
concentrations, nalidixic acid was found to be bacteriostatic and inhibit bacterial cell growth, 
while at higher concentrations it is bactericidal, killing bacterial cells. However, at the time, 
the use of nalidixic acid was limited due to its narrow-spectrum activity against Gram-
negative microorganisms. Thus, there was a need for nalidixic acid to undergo structural 
modification in order to attempt to improve its activity against a broader spectrum of 
microorganisms and therefore improve its clinical usefulness.  
 
Since the synthesis of nalidixic acid and discovery of its unique antimicrobial activity in the 
early 1960’s, fluoroquinolone class antibiotics have undergone four generations of clinical 
development. As in most antibiotic taxonomies, each generation has both structural 
characteristics and activity profiles that set it apart from other Fluoroquinolone structures by 
generation. The structures of nalidixic acid and select Fluoroquinolones from different 
generations of development are shown in the figures given below. Nalidixic acid and related 
acids were considered to be first generation quinolone-class agents. Structurally, nalidixic 
acid is a naphthyridone, not a quinolone, because its bicyclic core structure consists of two 
nitrogen atoms instead of one as in a quinolone core.  
 
The First Generation Quinolone - Nalidixic Acid
 
The switch to the quinolone core and introduction of a fluorine atom at C-6 and piperazine at 
C-7 in second generation derivatives, such as ciprofloxacin and norfloxacin, lead to 
increased spectrum activity and thus a larger range of infections that these agents could be 
used to treat. Addition of the N-1 cyclopropyl group, such as that in ciprofloxacin, was also 
found to be an important modification in increasing antibacterial activity.  
 
The Second Generation - Ciprofloxacin 
 
 
Further development of second generation derivatives with the introduction of new C-7 rings 
or chiral resolution of existing agents lead to third generation derivatives, such as 
levofloxacin. Third generation derivatives have demonstrated activity against Gram-positive 
bacteria and some penicillin resistant bacteria.  
 
The Third Generation - Levofloxacin 
 
 
The C-8 methoxy functionality was incorporated into the structures of current fourth 
generation fluoroquinolone agents, such as moxifloxacin and besifloxacin. The C-8 methoxy 
functionality is thought to contribute to increased activity against Gram-positive 
microorganisms, as well as decreased phototoxicity, a problem that was seen with some 
earlier agents. These agents demonstrate activity against anaerobic targets and some 
ciprofloxacin (a second generation fluoroquinolone) resistant targets. When looking at the 
history of fluoroquinolone development, important trends are observed that make 
Fluoroquinolones an important class of antibiotics for the future. 
 
The Fourth Generation - Moxifloxacin
 
 
 
The Fourth Generation - Besifloxacin
 
First, researchers are able to modify the structure of the fluoroquinolone to improve 
effectiveness against different kinds of microorganisms. While early generation 
Fluoroquinolones were effective against Gram-negative bacteria, the newer generation 
Fluoroquinolones have been developed to be more effective against Gram-positive bacteria. 
Additionally, researchers have successfully been able to modify the basic fluoroquinolone 
structure to gain antibiotic activity against bacterial mutants that arise and cause resistance. In 
the future, Fluoroquinolones could continue to undergo structural modifications in order to 
overcome the challenges faced by the on-going emergence of resistant microorganisms.  
Role of fluoroquinolones 
 
The ideal antibiotic agent, which could be used in conjunction with povidone-iodine, would 
have the four “killer Bs”:  
 Broad spectrum of activity  
 Bactericidal mechanism of action  
 Biocompatibility and  
 Bioavailability  
Bioavailability is especially important for antibiotic prophylaxis with cataract surgery; to be 
effective, an agent must penetrate the aqueous and, preferably, the vitreous humor. 
For this reason, fluoroquinolones have emerged in Europe and the United States as the 
mainstay of topical antibiotic prophylaxis. The two current generation ophthalmic 8-methoxy 
fluoroquinolones, available in the United States, moxifloxacin and gatifloxacin, are 
particularly active against gram-positive species while also maintaining an excellent gram-
negative effect. These agents are effective against endophthalmitis isolates that were resistant 
to the earlier generation fluoroquinolones ciprofloxacin, ofloxacin and levofloxacin (Mather 
R et al., 2002). The current generation fluoroquinolones are more efficacious against 
organisms that cause endophthalmitis in humans, notably S epidermidis, S aureus and S 
pneumoniae, than previous generations. 
Increased resistance to fluoroquinolones has been reported in keratitis, conjunctivitis and 
endophthalmitis isolates(Mah F.2003). Increasing antimicrobial resistance has been reported 
worldwide(Smith RD. 2002). 
Studies of ocular pathogens indicate many bacteria now have resistance to multiple types of 
drugs, including fluoroquinolones, cephalosporins and methicillin. In a 2001 study, none of the 
endophthalmitis isolates were susceptible to the older fluoroquinolones (Kowalski RP. 2003). 
A study by Blondeau and colleagues showed that the current generation fluoroquinolone 
gatifloxacin with benzalkonium chloride (BAK) has lower minimum inhibitory 
concentrations against a number of organisms than gatifloxacin without BAK. The 
combination of agent plus BAK was more effective than the agent alone; all clinical 
specimens of S pneumoniae tested, as well as a number of other strains, had lower MICs for 
the gatifloxacin solution with BAK than the drug without BAK. 
A similar study showed that the topical agent gatifloxacin 0.3% with BAK had a faster kill 
curve than the fluoroquinolone agent moxifloxacin 0.5% alone against several strains 
of Staphylococcus. The strains were inoculated to the two antibiotics, and serially diluted 
samples were incubated for 72 hours at 35° C. Test samples were assayed at 15, 30 and 60 
minutes. 
Gatifloxacin 0.3% killed the bacterial inoculum completely at 30 minutes in 16 of 17 test 
strains. At 60 minutes, no bacterial colony was recovered from topical gatifloxacin 0.3% in 
all strains. Moxifloxacin 0.5% reduced the bacterial inoculum by 60 minutes in all strains, but 
complete killing within 60 minutes was observed in only one strain. 
Bioavailability 
The bioavailability of an antibiotic can be assessed on the basis of how high a concentration it 
reaches in the tears, the cornea or other ocular tissues. Topical administration results in 
significant concentrations achieved in the tear film and on the cilia and meibomian glands. 
Penetration into the cornea can also be achieved, with subsequent distribution providing 
potentially therapeutic levels in the aqueous humor. 
Solomon and colleagues compared aqueous humor concentrations of two topically 
administered current generation fluoroquinolones and found that moxifloxacin achieved 
roughly twice the concentration of gatifloxacin in the aqueous humor in one study  (Solomon 
R et al., 2009). Additionally, moxifloxacin achieved a maximum concentration (Cmax) of 10 
times more than the MICs of most endophthalmitis-causing organisms (Solomon R et al., 
2009).  
A potentially protective concentration of moxifloxacin can be obtained in the aqueous humor 
of human patients with topical dosing prior to cataract surgery (Kim DHet 
al.,2005). Aqueous humor concentrations of 1.8 µg/mL for moxifloxacin and 0.48 µg/mL for 
gatifloxacin were achieved. The Cmax of moxifloxacin exceeded the known MICs of the 
organisms that most frequently caused endophthalmitis (Mah F. 2003). 
Topical administration of a current generation fluoroquinolone may prevent endophthalmitis 
even with a huge inoculum. In one animal study, one drop of moxifloxacin or saline solution 
was administered at 60, 45, 30 and 15 minutes before injection of a broth containing 0.025 
mL (5 × 104 colony-forming units) of S aureus into the anterior chamber of rabbits. After 
injection, four drops of moxifloxacin or saline solution were administered over 24 hours. At 
an examination at 24 hours, the moxifloxacin-treated rabbits did not develop clinical signs of 
endophthalmitis, while a large proportion of animals in the saline-treated group had signs of 
endophthalmitis (Kowalski RPet al., 2005). 
Once an organism reaches the vitreous, topical application of antibiotics is probably not 
efficacious to prevent infection. Costello and colleagues concluded that penetration of 
topically applied moxifloxacin and gatifloxacin into the vitreous in the uninflamed eye was 
not at significant levels to be protective against endophthalmitis(Costello Pet al., 2006). 
Besifloxacin is a new fluoroquinolone anti-infective developed for ophthalmic use, 
Theophthalmic suspension 0.6% (Besivance™) was recently approved for the treatment of 
bacterial conjunctivitis. The objective of this article by Proksch et al., (2009) is to provide a 
comprehensive overview of microbiological, pharmacokinetic/pharmacodynamic and clinical 
studies with besifloxacin. Microbiological studies have demonstrated that besifloxacin has 
wide-spectrum and potent activity against common ocular pathogens, including Gram-
negative and Gram-positive pathogens associated with bacterial conjunctivitis, and retained 
activity against fluoroquinolone-resistant staphylococci and multidrug-resistant strains. In 
preclinical and human studies, topically applied besifloxacin had a prolonged ocular 
concentration and minimal systemic exposure. In clinical studies, patients randomized to 
besifloxacin ophthalmic suspension 0.6% experienced significantly higher rates of clinical 
resolution and microbial eradication than patients randomized to vehicle. Besifloxacin 
ophthalmic suspension 0.6% was also found to be as effective and well tolerated as 
moxifloxacin ophthalmic solution 0.5%. The low minimum inhibitory concentrations and 
high attainment of pharmacodynamic targets with besifloxacin may contribute to a lower risk 
for the emergence of bacterial resistance, although further studies are needed. These data 
indicate that besifloxacin ophthalmic suspension 0.6% is an important new option for the 
treatment of bacterial conjunctivitis. 
 
The primary objective of a study by Karpecki Pet al.,(2009) was to compare the clinical and 
microbiologic efficacy of besifloxacin ophthalmic suspension 0.6% with that of vehicle (the 
formulation without besifloxacin) in the treatment of bacterial conjunctivitis. This was a 
multicenter, prospective, randomized, double-masked, vehicle-controlled, parallel-group 
study in patients with acute bacterial conjunctivitis. Patients received either topical 
besifloxacin ophthalmic suspension or vehicle administered 3 times daily for 5 days. At study 
entry and on days 4 and 8 (visits 2 and 3), a clinical assessment of ocular signs and symptoms 
was performed in both eyes, as well as pinhole visual acuity testing, biomicroscopy, and 
culture of the infected eye(s). An ophthalmoscopic examination was performed at study entry 
and on day 8.  And the conclusion of this study is the Besifloxacin ophthalmic suspension 
0.6% given 3 times daily for 5 days was both efficacious and well tolerated compared with 
vehicle in the treatment of these patients with bacterial conjunctivitis.  
 
McDonald MBet al.,(2009) compared the clinical and antimicrobial efficacy of besifloxacin 
ophthalmic suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the 
treatment of bacterial conjunctivitis. Multicenter, randomized, double-masked, parallel-
group, active-controlled, noninferiority study. A total of 1161 patients (533 with culture-
confirmed bacterial conjunctivitis) were randomized. Based on the 95% confidence interval 
(CI) of the difference, besifloxacin was noninferior to moxifloxacin for clinical resolution on 
day 5 (58.3% vs. 59.4%, respectively; 95% CI, -9.48 to 7.29) and day 8 (84.5% vs. 84.0%, 
respectively, 95% CI, -5.6% to 6.75%) and for microbial eradication on day 5 (93.3% vs. 
91.1%, respectively, 95% CI, -2.44 to 6.74) and day 8 (87.3% vs. 84.7%; 95% CI, -3.32 to 
8.53). 
 
There was no statistically significant difference between the 2 treatment groups for either 
efficacy end points on days 5 or 8 (P>0.05). Besifloxacin ophthalmic suspension was non 
inferior to moxifloxacin ophthalmic suspension and provided similar safety and efficacy 
(clinical and microbiological) outcomes when used for the treatment of bacterial 
conjunctivitis 
 
Cambau E. et al.,(2009) Besifloxacin is a new fluoroquinolone in development for ocular 
use. They investigated its mode of action and resistance in two major ocular pathogens, 
Streptococcus pneumoniae and Staphylococcus aureus, and in the reference species 
Escherichia coli. Primary and secondary targets of besifloxacin were evaluated by: (i) mutant 
selection experiments; (ii) MIC testing of defined topoisomerase mutants; and (iii) inhibition 
and cleavable complex assays with purified S. pneumoniae and E. coli DNA gyrase and 
topoisomerase IV enzymes. 
 
Although mutant selection experiments indicated that gyrase is a primary target, further 
biochemical and genetic studies showed that besifloxacin has potent, relatively balanced 
activity against both essential DNA gyrase and topoisomerase IV targets in S. aureus and S. 
pneumoniae. 
 
Comstock TLet al.,(2010)examined the efficacy and safety of besifloxacin ophthalmic 
suspension 0.6% in patients aged 1-17 years with bacterial conjunctivitis. This was a post hoc 
analysis of a subgroup of pediatric patients aged 1-17 years who had participated in three 
previously reported, randomized, double-masked, parallel-group, multicenter, clinical trials 
evaluating the safety and efficacy of besifloxacin in the treatment of bacterial conjunctivitis.  
 
This analysis included 815 pediatric patients aged 1-17 years (447 with culture-confirmed 
bacterial conjunctivitis). Clinical resolution was significantly greater (p < 0.05) in the 
besifloxacin group than in the vehicle group at both visit 2 (53.7% vs 41.3%) and visit 3 
(88.1% vs 73.0%). Similarly, microbial eradication was significantly higher with besifloxacin 
than with vehicle at visit 2 (85.8% vs 56.3%) and visit 3 (82.8% vs 68.3%). No significant 
differences in clinical resolution and microbial eradication were noted between besifloxacin 
and moxifloxacin. Besifloxacin was well tolerated, with similar incidences of adverse events 
in the besifloxacin, vehicle, and moxifloxacin groups. 
 
They concluded that Besifloxacin ophthalmic suspension 0.6% was shown to be safe and 
effective for the treatment of bacterial conjunctivitis in children and adolescents aged 1-17 
years. 
 
The study about  Human aqueous humor concentrations of besifloxacin, moxifloxacin, and 
gatifloxacin after topical ocular application was carried out by Donnenfeld EDet al.,(2011). 
To assess these concentrations relative to the minimum inhibitory concentration for 90% of 
strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of 
postoperative endophthalmitis. 
 
The aqueous humour drug concentrations were compared 60 minutes ± 5 minutes after 
instillation of 1 topical drop to patients aged 18 years or older having uncomplicated cataract 
surgery. Concentrations were determined using a validated liquid chromatography with 
tandem mass spectrometry method. Based on the aqueous humor drug concentrations 
measured in this study, it is unlikely that any of the fluoroquinolones tested would be 
therapeutically effective in the aqueous humour against the most frequently identified drug-
resistant staphylococcal isolates from recent cases of postoperative endophthalmitis. 
 
Silverstein BEet al.,(2011) has done the study evaluated the efficacy and tolerability of 
besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days compared with 
vehicle (formulation without besifloxacin) in the treatment of adults and children with 
bacterial conjunctivitis.This was a multicenter, prospective, randomized, double-masked, 
vehicle-controlled, parallel-group study. Patients aged ≥1 year with bacterial conjunctivitis 
were randomized to receive besifloxacin ophthalmic suspension or vehicle administered 
twice daily for 3 days. There were 3 study visits: the baseline visit, visit 2 (day 4 or 5), and 
visit 3 (day 7±1). Participants recorded the times of medication instillation in a patient diary. 
 
Tolerability assessments included ocular adverse events (AEs), changes in visual acuity, 
biomicroscopy and ophthalmoscopy findings, and nonocular AEs. Results for the individual 
clinical outcomes and microbial and clinical outcomes by gram-positive and gram-negative 
species were consistent with the primary efficacy outcomes. 
 
In these adults and children with bacterial conjunctivitis, treatment with besifloxacin 
ophthalmic suspension 0.6% administered twice daily for 3 days was effective and well 
tolerated. 
 
Wang Z et al., (2012) worked on the enantiometry of Besifloxacin hydrochloride, a novel 
chiral broad-spectrum fluoroquinolone developed for the treatment of bacterial conjunctivitis 
and reported. R-besifloxacin hydrochloride is used in clinics as a consequence of its higher 
antibacterial activity. To establish an enantiomeric impurity determination method, some 
chiral stationary phases (CSPs) were screened. Besifloxacin enantiomers can be separated to 
a certain extent on Chiral CD-Ph (Shiseido Co., Ltd., Japan), Chiral AGP, and Crownpak CR 
(+) (Daicel Chemical IND., Ltd., Japan). However, the selectivity and sensitivity were both 
unsatisfactory on these three CSPs. Therefore, Chiral AGP, Chiral CD-Ph, and Crownpak CR 
(+) were not used in the enantiomeric impurity determination of besifloxacin hydrochloride. 
The separation of enantiomers of besifloxacin was further performed using a precolumn 
derivatization chiral high-performance liquid chromatography method. 2,3,4,6-Tetra-O-
acetyl-beta-D-glucopyranosyl isothiocyanate was used as the derivatization reagent. 
Besifloxacin enantiomer derivates were well separated on a C(18) column (250 × 4.6 mm, 5 
μm) with a mobile phase that consisted of methanol-KH(2)PO(4) buffer solution (20 mm; pH 
3.0) (50:50, v/v). Selectivity, sensitivity, linearity, accuracy, precision, stability, and 
robustness of this method were all satisfied with the method validation requirement. The 
method was suitable for the quality control of enantiomeric impurity in besifloxacin 
hydrochloride. 
 
Malhotra Ret al.,(2013) carried out a multi-centre randomized work in which the objective 
was to compare the safety of besifloxacin ophthalmic suspension 0.6 %, administered three 
times a day for 7 days, with that of its vehicle. This randomized, multicenter, double-masked, 
vehicle-controlled, parallel-group study involved 518 patients ≥1 year of age with a clinical 
diagnosis of bacterial conjunctivitis. Patients were randomized 2:1 to treatment with 
besifloxacin 0.6 % ophthalmic suspension or vehicle, one drop in the infected eye(s) TID for 
7 days. 
 
Thirty-one ocular treatment-emergent adverse events (TEAEs) were reported by 28 subjects 
in the study eye; 19 occurred in 17/344 (4.9 %) besifloxacin patients, and 12 occurred in 
11/170 (6.5 %) vehicle patients (p = 0.5362). Only two ocular events (mild instillation site 
reaction, one case in each group) were considered "definitely related" to study treatment. One 
event of self-limited dysgeusia in the besifloxacin group was considered definitely related to 
treatment; there were no other nonocular TEAEs considered related to treatment. 
These findings indicate that besifloxacin ophthalmic suspension 0.6 % is safe in patients aged 
1 year and older when used TID for 7 days. 
The study to evaluate the role of besifloxacin in bacterial conjunctivitis treatment was carried 
out by Tracy D Mahvan et al.. (2014). They concluded that Besifloxacin 0.6% ophthalmic 
suspension 3 times a day for 5 days is safe and effective for BC. Twice-a-day dosing for 3 
days was also effective-a simplified regimen compared with other fluoroquinolones. 
Disadvantages include price and lack of a generic. Further evaluation is needed to evaluate 
comparative efficacy among other ocular fluoroquinolones and unlabeled uses. 
 
Intracellular Targets of Fluoroquinolones: 
Fluoroquinolones work by targeting and inhibiting DNA gyrase and/or Topoisomerase IV 
(Topo IV), both of which are type II bacterial topoisomerases involved in the DNA 
replication process. Type II topoisomerases function by breaking both strands of DNA, 
passing another segment of DNA through the break, and then religating the broken DNA. 
Specifically, they relax positive supercoils so that the DNA can unwind and replicate. More 
specifically, Topo IV’s primary role is that of a decatenase, while gyrase’s primary function 
is to relax positive supercoils. While DNA gyrase and Topo IV are similar in function, they 
are structurally distinct enzymes. Generally, DNA gyrase, composed of GyrA and GyrB 
subunits, is the primary target of Fluoroquinolones in Gram-negative bacteria, while Topo 
IV, composed of ParC and ParE subunits that are sometimes referred to as GrlA (names as 
gyrase-like) and GrlB subunits, is the primary target in Gram-positive bacteria. The ability of 
the fluoroquinolone class antibiotics to target type II topoisomerases offers several 
advantages over other antibiotic targets. First, type II topoisomerases are involved in DNA 
replication, an essential cell process that is universal to all bacteria. Second, type II 
topoisomerases are structurally unique enough from analogous human enzymes to allow for 
selectivity in targeting bacterial cells over human cells. Thirdly, the effect of target inhibition 
is bactericidal. Finally, Fluoroquinolones have the ability to potentially inhibit two distinct 
bacterial enzymes, thus reducing the possibility of selecting resistant mutants. All of these 
advantages demonstrate how fluoroquinolone class antibiotic agents have been, and will 
continue to be, attractive therapeutic options.  
 
Mechanism of Fluoroquinolone Action: 
The quinolone binds the DNA topoisomerase complex to form a ternary complex, which may 
lead to cell death by multiple pathways. Rapid cell death can occur via two different 
pathways: one requiring protein synthesis and one that does not. Cm = chloramphenicol, a 
known protein synthesis inhibitor. Adapted from  Cm (protein synthesis-dependent) 
(proteinsynthesis-independent) SDS-dependent release of DNA breaks after cell lysis Blocks 
growth and  form a ternary complex with the DNA and DNA gyrase/Topo IV, which then 
becomes trapped, disrupts replication, and triggers various cell death mechanisms. 
Topoisomerase binds and nicks each DNA strand in the replication process, with four DNA 
base pairs in between the nicked sites. The fluoroquinolone then binds the 
topoisomerase/nicked DNA complex in each of the nicked sites.  
 
However, it is not certain as to what the exact order of binding is. Once the ternary complex 
is formed, different mechanisms of cell death are observed by different Fluoroquinolones. 
With older generation Fluoroquinolones, such as nalidixic acid and ciprofloxacin, slow cell 
death is observed. In vitro work with purified enzyme shows that ternary complex formation 
is fully reversible after the older generation drugs are removed because DNA religation is 
observed. However, with newer Fluoroquinolones, such as moxifloxacin, rapid cell death is 
observed. With these agents in the in vitro purified enzyme assays, all of the DNA is not 
religated after the fluoroquinolone is removed. In cells, this effect is observed as 
chromosomal fragmentation. Rapid cell death also appears to be able to occur via two 
different mechanisms: one requiring protein synthesis and the other in the absence of protein 
synthesis. For example, prior to MIC assays, chloramphenicol (Cm), a known protein 
synthesis inhibitor, can be added to stop protein synthesis. Some Fluoroquinolones will kill in 
the presence of Cm, while others do not. The structural requirements for a fluoroquinolone to 
kill or not kill in the presence of Cm (absence of protein synthesis) are not known. 
Additionally, fluoroquinolone interactions with DNA may contribute to which mechanism of 
cell death are observed.  
The retrospective study included data from over 16,000 procedures and compared the rates of 
endophthalmitis over three different time periods during which endophthalmitis prophylaxis 
protocols varied.  During 2007, only topical drops were used postoperatively. Intracameral 
cefuroxime was added except in patients with allergy or posterior capsule rupture during 
2008 and 2009, while during 2010 and 2011, patients received both topical and intracameral 
antibiotics. However, the intracameral agent could be cefuroxime, moxifloxacin, or 
vancomycin  based  on  surgeon  preference,  and there were no exclusions to cefuroxime use.  
Rates of postoperative endophthalmitis declined from 0.31% with topical antibiotic drop use 
to 0.14% with initiation of intracameral antibiotics, and then to just 0.01% during the last 2 
years of the study. 
Fig.  10 
 
Subconjunctival injection of a steroidal drug maintains the drug in the eye 
for as long as six weeks, eliminating another postop drop 
 
But as much as the prophylactic approach in phacoemulcification of cataract cases is topical 
application of antibiotics of the surgeon's choice. Based on review of the available evidence 
and its quality, the strongest support exists for using povidone-iodine antisepsis and 
topically applied antibiotics (Packer M, et al., 2012). Moxifloxacin 0.5% ophthalmic 
solution (Vigamox, Alcon) is being used by some surgeons because it is a convenient, off-
the-shelf, preservative-free formulation, and it appears to have good safety in terms of risks 
of toxic anterior shock syndrome (TASS) and CME according to several published reports. 
The current trend in busy ophthalmic centres is the fourth generation fluoroquinolone 
antibiotic -  Besifloxacin that has almost the same three advantageous points similar to 
moxifloxacin. For those three reasons—tonicity, pH and absence of preservative—off-the-
shelf Besivance
®
 is compatible with the intraocular environment and is tolerated 
intracamerally too without dilution.” 
 
Hence Besifloxacin has been taken up for this study to investigate penetration and 
effectiveness on topical application through conventional mode of administration and in 
pulse mode of administration. 
  
 
 
 
 
 
 
 
 
Drug Profile 
III. DRUG PROFILE 
 
BESIFLOXACIN 
 
CLASS  : Ophthalmological Anti-infective 
DESCRIPTION : Besifloxacin is a fourth-generation fluoroquinolone antibiotic. 
Ophthalmic suspension used to treat bacterial conjunctivitis. 
COMMON BRAND(S): Besipact; Besivance 
 
GENERIC NAME(S):  BesifloxacinHCl 
 
MOLECULAR WEIGHT:     393.843 g/mol 
MOLECULAR FORMULA: C19H21CLFN3O3 
MOLECULAR STRUCTURE: 
 
 
MECHANISM OF ACTION: 
Besifloxacin is a bactericidal fluoroquinolone–type antibiotic that inhibits bacterial enzymes, 
DNA gyrase and topoisomerase IV. By inhibiting DNA gyrase, DNA replication, 
transcription, and repair is impaired. By inhibiting topoisomerase IV, decatenation during cell 
division is impaired. Inhibiting these two targets also slows down development of resistance. 
 
 
DOSAGE &INDICATION 
Treatment of bacterial conjunctivitis 
Bacterial isolates that are susceptible to besifloxacin include:  
 
 Corynebacteriumpseudodiphtheriticum 
 Corynebacterium striatum 
 Haemophilus influenza 
 Moraxella lacunata 
 Staphylococcus aureus 
 Staphylococcus epidermidis 
 Staphylococcus hominis 
 Staphylococcus lugdunensis 
 Streptococcus mitis 
 Streptococcus ralis 
 Streptococcus pneumonia 
 Streptococcus salivarius 
 
OPHTHALMIC DOSAGE 
Adults, Adolescents, and Children 
Instill 1 drop in the affected eye(s) 3 times daily, 4 to 12 hours apart, for 7 days. 
 
CONTRAINDICATION / PRECAUTIONS 
General Information 
Besifloxacin is for topical ophthalmic use only and should not be injected subconjunctivally 
or introduced directly into the anterior chamber of the eye. 
 
 
Quinolone hypersensitivity 
The manufacturer does not specifically provide a caution in using besifloxacin, an 8-chloro 
fluoroquinolone, in patients with a history of quinolone hypersensitivity; however, it seems 
reasonable that caution should be exercised in cases of known allergy. 
 
Contact lenses 
Patients should not wear contact lenses during the treatment of bacterial conjunctivitis with 
besifloxacin. 
 
Fungal infection 
Prolonged use of besifloxacin may result in the overgrowth of non-susceptible organisms. If 
superinfection, including fungal infection, occurs, patients should discontinue besifloxacin 
use and institute alternative therapy. 
 
Geriatric 
No safety and efficacy differences with besifloxacin have been reported between geriatric and 
younger patients. 
 
Infants, neonates 
The safety and efficacy of besifloxacin have not been established in neonates and infants less 
than 1 year of age. Efficacy of besifloxacin in children one year and older has been 
established in clinical trials. The manufacturer states that there is no evidence that ophthalmic 
administration of quinolones has any effect on weight bearing joints. 
 
Pregnancy 
No adequate and well-controlled studies with besifloxacin have been conducted in pregnant 
women and its ability to cause fetal harm or affect reproductive capacity is unknown. In 
animal studies, the No Observed Adverse Effect Level (NOAEL) for embryo-fetal 
development was 100 mg/kg/day (Cmax 5 mcg/mL or greater than 11,000-times the mean 
serum concentration measured in humans). 
 
Low serum concentrations have been observed during ophthalmic administration (e.g., less 
than 1.3 ng/mL). To minimize the amount of drug that reaches systemic circulation, apply 
pressure over the tear duct by the corner of the eye for 1 minute after each administration. 
The manufacturer recommends that besifloxacin be used during pregnancy only if the 
potential benefits to the mother outweigh the potential risk to the fetus. 
Breast-feeding 
There are no data on the presence of besifloxacin in human milk, the effects on the breastfed 
infant, or the effects on milk production. It is not known whether measurable concentrations 
of besifloxacin would be present in maternal milk after topical ocular administration; 
however, systemic exposure after ocular administration is low. The low maternal serum 
concentrations (less than 1.3 ng/mL) suggest exposure to a nursing infant would likely be 
clinically insignificant. To minimize the amount of drug that reaches systemic circulation and 
breast milk, apply pressure over the tear duct by the corner of the eye for 1 minute after each 
administration. The manufacturer suggests caution when administering to lactating women. 
Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk 
of an untreated or inadequately treated condition. If a breast-fed infant experiences an adverse 
effect related to a maternally administered drug, health care providers are encouraged to 
report the adverse effect to the FDA. 
 
PHARMACOKINETICS 
Besifloxacin is applied topically to the eye. Systemic absorption is minimal. The mean 
elimination half-life after multiple doses was estimated to be 7 hours. 
 
Ophthalmic Route  
Systemic absorption of besifloxacin is minimal. Serum concentrations were measured in 
adults with suspected bacterial conjunctivitis receiving besifloxacin bilaterally three times 
daily (16 doses total). After both the first and last dose, maximum serum concentrations were 
less than 1.3 ng/mL with a mean Cmax of 0.37 ng/mL on day 1 and 0.43 ng/mL on day 6. 
 
MAXIMUM DOSAGE 
Adults 
3 drops/eye/day. 
Elderly  
3 drops/eye/day. 
Adolescents 
3 drops/eye/day. 
Children 
3 drops/eye/day. 
Infants 
Safety and efficacy have not been established. 
DOSING CONSIDERATIONS 
 
Hepatic impairment 
Specific guidelines for dosage adjustment in hepatic impairment are not available; it appears 
that no dosage adjustments are needed. 
Renal Impairment 
Specific guidelines for dosage adjustment in renal impairment are not available; it appears 
that no dosage adjustments are needed. 
 
ABSORPTION: 
 
 Although ocular surface concenetrations are high, average systemic concenetrations after 
three –times daily dosing was less than 0.5 ng/mL. This indicates that besifloxacin is not 
appreciably absorbed into the systemic and has a very low risk of systemic side effects. 
 
Volume of distribution: 
Not absorbed into the systemic 
Protein binding: 
None 
Metabolism : 
No appreciable metabolism 
Route of elimination: 
N/A 
Half life: 
The average elimination half –life of besifloxacin in plasma following multiple dosing was 
estimated to be 7 hours. 
Clearance: 
N/A 
Toxicity: 
LD50 Rat: >2000mg/kg. The most common adverse effects reported in 2% of patients treated 
with besifloxacin was conjunctival redness. 
 
 
PHARMACODYNAMICS 
Besifloxacin is a fluoroquinolone that has a broad spectrum in vitro activity against a wide 
range of Gram-positive and Gram-negative ocular pathogens: e.g., 
 
 Corynebacterium pseudodiphtheriticum 
 Moraxella lacunata 
 Staphylococcus aureus 
 Staphylococcus epidermidis 
 Staphylococcus hominis 
 Streptococcus mitis 
 Streptococcus oralis 
 Streptococcus pneumoniae and  
 Streptococcus salivarius. 
 
Besifloxacin has been found to inhibit production of pro inflammatory cytokines in vitro. The 
mechanism of action of besifloxacin involves inhibition of two enzymes which are essential 
for the synthesis and replication of bacterial DNA: the bacterial DNA 
gyrase and topoisomerase IV. 
DRUG INTERACTION/S 
There are no drug interactions associated with Besifloxacin products. 
 
ADVERSE EFFECTS 
During the treatment, the most frequently reported ocular adverse reaction was the 
appearance of conjunctival redness (approximately 2% of patients). Other possible adverse 
reactions, reported in subjects treated with besifloxacin were: eye pain, itching of the eye, 
blurred vision, swelling of the eye or eyelid, severe dizziness, troubled breathing.  
Moderate ADR 
Blurred vision / Early / 1.0-2.0 
Conjunctivalhyperemia / Early / 2.0-2.0 
Superinfection / Delayed / Incidence not known 
 
Mild ADR  
Ocular irritation / Rapid / 1.0-2.0 
Ocular pruritus / Rapid / 1.0-2.0 
Ocular pain / Early / 1.0-2.0 
Headache / Early / 1.0-2.0 
 
 
OPHTHALMIC ADMINISTRATION 
 For topical ophthalmic administration only 
 Wash hands prior to use 
 Remove contact lenses prior to use 
 Prior to administration, invert the closed bottle and shake once 
 Remove the cap while the bottle is in the inverted position and administer one drop 
into the affected eye(s)  
 Do not rinse the dropper after use; keep container tightly closed 
 Use one bottle per patient; do not share ophthalmic drops 
STORAGE & DISPOSAL OF BESIFLOXACIN 
 Store at room temperature. Do not freeze. 
 Protect from light. 
 Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets. 
 Check with your pharmacist about how to throw out unused drugs. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Need for the Present Study 
IV. NEED FOR THE PRESENT STUDY 
 
According to World Health Organization, Cataract is the preventable blindness throughout 
the world. Unlike Infectious disease Specialists of Internal Medicine, Ophthalmologists have 
the advantage of being able to place an antibiotic agent directly on the target tissue (topically) 
without excessive direct concern for issues such as volume of distribution or the metabolism 
of the drug. Whether the prophylactic effect of topical administration of antibiotics in cataract 
surgery can be augmented by the addition of intracameral administration remains a topic of 
discussion. 
Ocular Pharmacokinetics of the Anterior Segment 
The anterior segment of the eye constitutes  
o CORNEA 
o CONJUNCTIVA 
o AQUEOUS HUMOR 
o LENS 
o IRIS AND CILIARY BODY (ICB).  
The primary routes for drug delivery to the anterior segment include   - 
o Topical administration 
o Subconjunctival, and  
o Intracameral injections.  
Pharmacokinetics  
Pharmacokinetic processes involved with each of these major routes of administration are as 
follows:  
After Topical Administration: 
Topical administration is the most convenient route of drug delivery to the anterior segment 
of eye. Following topical instillation, majority of the administered drug is cleared rapidly 
from the ocular surface resulting in only 1–7% of the dose to reach the aqueous humor 
(Ghate  and  Edelha  user  2006).   Precorneal  clearance  mechanisms  including  tear  fluid  
turnover and blinking, selective permeability of the corneal epithelial barrier, and drug loss 
through naso-lacrimal as well as systemic circulation attribute to the low bioavailability of 
drugs administered by this route. 
 
Factors Affecting Absorption and Bioavailability 
The critical factors that may affect the absorption process and alter the intraocular 
bioavailability of topical drops consist of physiological factors relevant to ocular tissues and 
molecular properties unique to drugs. A complete understanding of the interaction between 
these factors is essential to enhance the pharmacokinetic processes.  
 
Loss of Drug from the Precorneal Surface 
The tear volume in humans under normal condition is 7–9 μL with a turnover rate of 0.5–2.2 
μL/min. Many commercially available eyedroppers deliver a typical volume of 25–56 μL to 
the precorneal tear film resulting in an increase in the tear volume. Under normal conditions, 
human palpebral fissure can hold 30 μL without overflowing. This abrupt increase in the 
volume due to topical instillation causes reflex blinking and rapid drainage from ocular 
surface. Majority of the applied medication is drained from the surface through the 
nasolacrimal duct and eventually cleared via systemic circulation.  
 
Drug Properties Affecting Absorption 
In case of topically administered drugs, absorption through cornea may occur via 
transcellular or paracellular pathways or by active transport. Drug properties that influence 
these processes such as lipophilicity and aqueous solubility play a key role in the penetration 
of drugs across cornea. Lipophilicity (LogP) in the range of 2–3 was found to be optimal for 
corneal permeation of steroids and β-blockers (Schoenwald and Huang 1983). An 
exploratory analysis of the apparent corneal permeability (Papp) values for more than 100 
compounds indicated that corneal permeability is dependent on the distribution coefficient - 
LogD at experimental pH (Prausnitz and Noonan 1998). As the dataset was mostly 
comprised of small molecules, no apparent dependency on molecular weight was observed. 
Further analysis of this permeability data with other molecular descriptors revealed potential 
correlation of corneal permeability with polar surface area (PSA).  
PSA is the sum of surfaces of polar atoms, primarily oxygen, nitrogen, and their attached 
hydrogen atoms. PSA along with lipophilicity and molecular size influence the passive 
diffusion of molecules. Due to the hydrophilic nature of corneal stroma, highly lipophilic 
compounds have limited permeability across this tissue. Stromal permeability data from a 
limited number of molecules (N ¼ 19) indicated a strong dependence on its molecular weight 
and radius but no apparent relationship with any of the lipophilicity indicators (LogP or 
LogD) (Prausnitz and Noonan 1998) . As indicated earlier, stroma is a thick, fibrous, and 
hydrophilic tissue where diffusion plays a major role in the transport of molecules. Thus 
stromal permeability is negatively correlated with molecular weight and radius, the 
parameters that affect the diffusion of a compound. Permeability of corneal endothelium 
shows a good correlation with both LogD and molecular radius indicating the role of both 
lipophilic and hydrophilic pathways. Similar to intact cornea, an increase in the corneal 
endothelial permeability was observed with a moderate increase in lipophilicity. However, 
the data was limited by the absence of highly lipophilic compounds to further investigate the 
barrier properties. Due to the presence of large intercellular junctions and leaky nature of the 
endothelial layer, strong correlation was observed with molecular radius. In general, taking 
into consideration the overall data, corneal epithelium serves as main barrier to transport of 
molecules across cornea. Small molecules with favourable lipophilicity readily cross corneal 
epithelium but stroma may provide a barrier to macromolecules. Several formulation 
approaches are employed to overcome the absorption barriers and improve the ocular 
bioavailability. More information on these can be found in a recent review article (Ghate and 
Edelhauser 2006). 
 
Distribution of Drugs in the Anterior Segment of Eye: 
Topically administered drugs permeate across the cornea and enter the aqueous humor 
followed by distribution to the surrounding ocular tissues including iris–ciliary body, lens, 
choroid–retina, and vitreous (Ghate and Edelhauser 2006). Drugs that may exhibit non-
corneal routes of absorption enter the uveal tract and vitreous without entering the aqueous 
humor. The rate and extent of drug distribution in the anterior segment is determined by a 
number of factors including permeability, diffusion in the aqueous humor, binding to proteins 
and surrounding ocular tissue components. Most of these factors are influenced by a                 
drug’s physicochemical  properties including lipophilicity, solubility, and  molecular  weight.                    
The apparent volume of distribution (Vd) of drugs can be measured by direct administration 
into the aqueous humor (intracameral). However, there is a paucity of data on the 
pharmacokinetics of drugs following intracameral injection. Based on the volume of aqueous 
humor in rabbits (0.3 mL), the Vd ranged from two- to tenfold larger than the aqueous humor 
volume. Although no clear trend was observed between Vd and molecular weight or LogP, 
drugs with higher protein binding had a lower Vd in the aqueous humor. Drugs that 
extensively bind to plasma proteins were known to exhibit a low Vd and can have a long 
plasma half-life. Flurbiprofen, a highly protein bound drug, has a longer elimination half-life 
in aqueous humor when compared to other moderate to weakly bound drugs. For topically 
administered drugs, protein binding occurs first in the tear fluid which has a rapid turnaround 
time and as a result only the free unbound drug is available for corneal absorption. More 
binding of the absorbed drug occurs in the cornea and aqueous humor. Protein content of the 
aqueous humor is different when compared to plasma. Concentration of proteins in the 
aqueous humor is approximately 200 times less than in plasma. However, these levels may 
increase in certain disease states that involve inflammatory conditions and subsequently 
result in increased binding of drugs. The effect of protein binding was investigated by adding 
increasing amounts of rabbit serum albumin to pilocarpine solution before topical 
administration (Mikkelsonet al., 1973). The results indicated a 75- to 100-fold reduction in 
response (pupillary diameter) by the addition of 3% albumin indicating a decreased 
bioavailability as a result of protein binding. Nevertheless, more data comparing the 
pharmacokinetics of drugs in normal versus diseased state (e.g., inflammation, blood-aqueous 
barrier breakdown, etc.) is required to understand the effect of protein binding on the 
disposition of topically administered drugs. From a therapeutic perspective, distribution of a 
drug to its target site is essential to achieve the desired efficacy. Although measurement of 
drug concentration in the aqueous humor provides an estimation of Vd, measuring drug levels 
in the surrounding ocular tissues is required to assess if the drug has reached the site of 
action. While pharmacokinetic studies with extensive tissue distribution data are scarce, few 
studies report the drug concentrations in key ocular tissues in addition to the aqueous humor. 
Given the number of animals required and the destructive nature of tissue sample collection, 
this is not uncommon in the ophthalmology field.  
 
As expected, the relative exposure was higher in the cornea following topical instillation of 
drugs. The relative exposure in cornea was several folds higher for high molecular weight 
compounds (azithromycin and cyclosporin) when compared to other drugs. Also, the relative 
exposure of drugs in iris–ciliary body is higher than in aqueous humor. With the exception of 
lomefloxacin, for which data was available from infected rabbit eyes, the relative exposure in 
ICB decreased with increasing lipophilicity (LogP). Several explanations have been 
postulated to explain this higher exposure in ICB (Schoenwald 2003). Iris of rabbit eye is a 
porous and highly vascular tissue with majority of its surface area exposed to aqueous humor 
thereby allowing extensive distribution from aqueous humor. Further, an increased 
affinity/capacity for binding to melanin pigment in the iris could enhance the distribution to 
this tissue. Brimonidine, a drug well known to bind melanin, has higher relative exposure in 
ICB than in cornea. Levobetaxolol, a cardioselective beta-adrenergic receptor blocking agent, 
has higher affinity to melanin with ICB exposure several folds higher than in aqueous humor.  
 
An alternative explanation for the higher exposure in ICB could be due to potential 
contribution of non-corneal absorption routes via conjunctival/scleral pathways. Based on 
their physicochemical properties, certain drugs may be preferentially absorbed by conjunctiva 
and sclera to reach ICB without entering the aqueous humor. Chien DS.et al., (1990) 
investigated the ocular absorption via corneal and conjunctival/scleral routes of clonidine, p-
aminoclonidine, and AGN 190342 after drug perfusion in vivo. When drug was maintained 
over the conjunctiva over a period of time, the rank order of drug concentration in the 
anterior chamber tissues was: 
Conjunctiva >Cornea >Ciliary body >Aqueous humor;  
whereas, when drug solution was in contact with cornea, the rank order for tissues was: 
Cornea >Aqueous humor>Ciliary body >Conjunctiva. 
 
Besides, the conjunctival/scleral pathway was contributed as the predominant pathway for the 
least lipophilic (p-aminoclonidine) compound. Further experiments carried out using beta-
blocking agents with varying lipophilicity, sucrose and inulin demonstrated that the outer 
layer of sclera provides less resistance to penetration of hydrophilic drugs when compared to 
cornea (Ahmed and Patton 1985). Moreover, the estimated permeability of conjunctival and 
scleral tissues was found to be 15–25 times higher than the cornea and was not affected by 
molecular size (Hamalainen et al., 1997).  
In more recent data from the Bascom Palmer Eye Institute between 2000 and 2005, the rate 
of endophthalmitis after cataract surgery did not increase significantly with topically applied 
fluoroquinolones (Miller et al., 2006). Risk factors for endophthalmitis between 2000 and 
2005, included systemic immuno-suppression, the method of operative preparation, intra-
operative complications such as vitreous loss, peri operative factors such as the presence of 
surface bacteria, wound construction factors such as wound leak and inferior incision 
placement, and the presence of chronic blepharitis. 
  
The role of topical antibiotic prophylaxis is to reduce the colonization with the organisms of 
the periocular flora on the ocular surface, as the patient’s own flora are often the cause of 
endophthalmitis. Other studies support that gram-positive, coagulase-negative organisms, 
notably Staphylococcus epidermidis, are the predominant causative agents in cases of 
endophthalmitis (Han et al.,1996  andSpeaker MG & Menikoff JA. 1991). 
 
Goals of prophylaxis 
The goals of prophylaxis must be taken into account when considering a Regimen to reduce 
the risk for infection. 
 
A second goal of antibiotic prophylaxis is to eradicate the organisms that may enter the eye. 
Natural host defence mechanisms in the eye are efficient at removing inoculations to a 
degree, but a therapeutic concentration of antibiotic is needed when the contamination 
exceeds the capacity of the aqueous humour to adequately clear an organism. Possible modes 
of administration include sub-conjunctival injections, placement of antibiotics in the infusion 
fluid, oral systemic administration and topical administration.  
 
Although a recent study by members of the European Society of Cataract and Refractive 
Surgeons concluded that intracameral administration of cefuroxime reduced the incidence of 
postoperative endophthalmitis, the preparation used for intracameral administration in the 
study is neither commercially available in the United States nor approved for ophthalmic use 
by the US FDA (Barry et al., 2006). Because of the need for compounding antibiotics,   
errors  in  dilution or  loss  of  sterility  may  occur.  Rarely, patients  exhibit  hypersensitivity 
to beta lactam antibiotics. In addition, this cephalosporin is not effective against                       
methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus 
epidermidis (MRSE), Enterococcus faecalis or Pseudomonas aeruginosa. With multiple 
doses prepared in a single container, contamination with P aeruginosa may occur. 
 
With a compounded antibiotic preparation administered intraocularly, the possibility of toxic 
anterior segment syndrome (TASS) exists. TASS is an acute, noninfectious sterile 
inflammatory condition of the anterior segment that results from a number of causes, 
including irrigating solutions or medications outside a tolerable range of pH, medications in 
toxic concentrations, cleaning agents, organic material biofilms or toxic residues (Mamalis N 
et al., 2007).
 
An increased incidence of cystoid macular edema has also been reported in 
relation with use of intracameral antibiotics in the infusion fluid (Axer-Siegel R et al., 
1999). 
 
Considering all the above facts of varying formulation parameters of antimicrobial eye drops 
for topical administration and the pharmacokinetic profile of these compounds the hitherto 
not much explored fluoroquinolone is taken up for this study. 
 
The current trend in busy ophthalmic centres is the fourth generation fluoroquinolone 
antibiotics. A lot of clinical data is available on the fourth Gen Moxifloxacin and  
Gatifloxacin and on the third generation Levofloxacin. Whereas not much clinical data is 
available on Besifloxacin, yet another fourth gen fluoroquinolone that has almost the same 
three advantageous points similar to moxifloxacin.For those three reasons—tonicity, pH and 
absence of preservative—off-the-shelf Besivance® is compatible with the intraocular 
environment and is tolerated intracamerally too without dilution.” 
 
Hence Besifloxacin has been taken up for this study to investigate its corneal penetration 
power and its effectiveness on topical application by two modes namely the ‘Conventional 
two-days mode’ of administration and the ‘Pulse mode’ of administration an hour  before the 
procedure. 
  
 
 
 
 
 
 
 
 
Aim & Objective 
V. AIM & OBJECTIVE 
 
AIM 
The aim is to study the bactericidal activity on conjunctival flora of topically applied 
Besifloxacin by two different modes of administration  
- The Conventional mode of administering one drop of sterile antimicrobial 
eye drop since two days prior to surgery four times a day(Regimen A) 
& 
- The Pulse modeof administration starting an hour immediately preceding 
surgery – 6 doses delivered every 10 minutes(Regimen B) 
 
OBJECTIVE 
- To determine, the penetration of Besifloxacin in aqueous humour 
withdrawn from the anterior chamber, by High Performance Liquid 
Chromatography 
 
- To study the prevalence of associated diseases that cause cataract 
secondarily 
 
- To find the type of cataract that prevails more in the study groups 
 
- To find the most effective way of administering the drops for better 
penetration of the eyes 
 
 
 
 
  
 
 
 
 
 
 
 
 
Plan of the Work 
VI. PLAN OF THE WORK 
 
The entire study has been planned to be carried out for a period of nine months from 
NOVEMBER 2017 to AUGUST 2018. The proposal was designed as given below: 
 
NOVEMBER- DECEMBER 2017   (2 Months) 
 Literature Review 
 Obtaining consent from Hospital authorities 
 Study Design and Data Entry Format (Proforma) 
 Obtaining  approval  from Institutional Ethics Committee (IEC) 
 
JANUARY- JUNE 2018     (6 Months) 
 Selection of Patients 
 Collection of Patients’ details 
 Collection of Samples 
 Collection of Lab and other investigation Reports 
 
JULY-AUGUST- SEPTEMBER 2018     (2 months) 
 Compilation 
 Data analysis 
 Submission of Report 
 
 
 
  
 
 
 
 
 
 
 
 
Methodology 
VII. METHODOLOGY 
 
MATERIALS AND METHODS 
Study site :  Vasan Eye Care Hospital, Tiruchirappalli 
 
Study period:  The study was conducted during a nine month period. 
 
Inclusion criteria: 
  
 The subjects of either sex (otherwise healthy) who were scheduled to undergo 
standard cataract surgery 
 21years of age or older 
 Having a normal or lesser intraocular pressure 
 Had the ability to understand and give signed informed consent. 
 
Exclusion criteria: 
 
 Those that exhibited any intraocular inflammation 
 Had a known sensitivity to any of the ingredients in the study medications  
 Had a known sensitivity to any quinolone compound 
 Had a condition that may confound the study results or may interfere significantly 
with the subject’s participation in the study 
 Had a greater intraocular pressure 
 Exhibiting a corneal ulcer, keratitis, or had a history of herpetic keratitis,  
 Had any ocular disease that would interfere with the evaluation of the study 
treatments 
 Received previous intraocular silicone oil 
 Was pregnant or nursing. 
 
 
METHOD OF STUDY 
 
Fifty select patients undergoing cataract extraction were divided randomly into two groups 
with 0.5% Besifloxacin ophthalmic solution topically applied in both the groups: 
 0.5%Besifloxacin‐25 patients under REGIMEN–A and  
 0.5%Besifloxacin‐25 patients under REGIMEN-B. 
Regimen A: 1 drop four times a day for two days ( 8 drops) – 25 patients and 
Regimen B: 1 drop – 6 doses - delivered every 10 min in the hour immediately preceding      
surgery (6 drops) ‐25 patients. 
Regimen A: 
Two days before surgery the patient’s conjunctival smear was taken as a baseline. Then the 
assigned drug was given randomly to each patient at a dose of a drop four times a day for two 
days. After two days of administration at the time of surgery a second smear was taken to 
assess the bacterial load to find the efficacy of the drug under Regimen A. 
Regimen B: 
Conjunctival smear was taken as a baseline before start of administration of Besifloxacin on 
the day of surgery and the drug administered every tenth minute a drop for an hour; and at the 
time of surgery a second smear was taken to assess the bacterial load to find the efficacy of 
the drug under Regimen B.  
Fig.  11 
Various Ophthalmic Routes of Administration  
 
 
 
 
  
Fig.  12 
 
Structures of the eye  -labelled 
 
 
 
 
 
 
 
Fig.  13 
 
The lower part of the right eye after a Central and Horizontal section 
 
 
 
During surgery 0.2 ml of aqueous humour was aspirated with the help of a tuberculin syringe. 
The anterior chamber fluid was immediately placed into a sterilized cryogenic tube and 
stored at ‐40° C in an refrigerator and kept frozen until analysis was performed. Each tube 
was marked with a patient identification number (which indicated the antibiotic that the 
subject was randomly assigned), the subject's initials, date of surgery, and eye (R/L).  
 
 
Conjunctival swab material was inoculated into 0.3 ml of sterile saline in a sterile vial. The 
swab was repeatedly twirled in the saline. In the laboratory, 0.1ml of the saline was 
inoculated onto a plate of 5% sheep blood agar while 0.05 ml each was inoculated onto a 
plate of Nutrient agar and a plate of MacConkey agar. 
 
Nutrient Agar is a general purpose, nutrient medium used for the cultivation of 
microbes supporting growth of a wide range of non-fastidious organisms. Nutrient agar is 
popular because it can grow a variety of types of bacteria and fungi, and contains many 
nutrients needed for the bacterial growth. 
 
TABLE: 1 
Composition of Nutrient Agar 
Ingredients Note 
0.5%  Peptone 
(Pancreatic digest of gelatin) 
It is an enzymatic digest of animal protein. 
Peptone is the principal source of organic 
nitrogen for the growing bacteria 
0.3% beef extract/yeast extract 
It is the water-soluble substances which aid in 
bacterial growth, such as vitamins, carbohydrates, 
organic nitrogen compounds and salts 
1.5% agar 
It is the solidifying agent 
 
0.5% NaCl 
The presence of sodium chloride in nutrient agar 
maintains a salt concentration in the medium that 
is similar to the cytoplasm of the microbes 
Distilled Water 
Water is essential for the growth of and 
reproduction of micro-organisms and also 
provides the medium through which various 
nutrients can be transported. 
 
Final pH is adjusted to neutral (7.4) at 25 °C. 
 
 
 
 
 Preparation of Nutrient Agar 
 
1. Suspend 28 g of nutrient agar powder in 1 litre of distilled water 
2. Heat this mixture while stirring to fully dissolve all components 
3. Autoclave the dissolved mixture at 121°C for 15 minutes 
4. Once the nutrient agar has been autoclaved, allow it to cool but not solidify 
5. Pour nutrient agar into each plate and leave plates on the sterile surface until the agar has     
solidified 
6. Replace the lid of each Petri dish and store the plates in a refrigerator 
Uses of Nutrients Agar 
 
1. It is frequently used for isolation and purification of cultures 
2.  It can also be used as a means for producing the bacterial lawns needed for antibiotic 
sensitivity tests.  In actuality, antibiotic sensitivity testing is typically performed on 
media specially formulated for that purpose 
 
 
 
 
 
 
Fig.  14 S. aureus in nutrient agar 
 
 
Fig. 15   S. epidermidis in nutrient agar 
 
 
Fig.  16 
Four nutrient agar plates showing colonies of common Gram negative 
bacteriae 
 
 
 
MacConkey agar (MAC) is a selective and differential media used for the isolation and 
differentiation of non-fastidious gram-negative rods, particularly members of the family 
Enterobacteriaceae and the genus Pseudomonas. 
TABLE: 2 
Composition of MacConkey Agar 
Ingredients Amount 
Peptone (Pancreatic digest of gelatin)  17 gm 
Proteose peptone (meat and casein) 3 gm 
Lactose monohydrate  10 gm 
Bile salts 1.5 gm 
Sodium chloride 5 gm 
Neutral red 0.03 gm 
Crystal Violet 0.001 g 
Agar 13.5 gm 
Distilled Water Add to make 1 Litre 
Final pH 7.1 +/- 0.2 at 25 degrees C. 
 
Uses of MacConkey Agar 
1. MacConkey agar is used for the isolation of gram-negative enteric bacteria 
2. It is used in the differentiation of lactose fermenting from lactose non-fermenting 
gram-negative bacteria 
3. It is used for the isolation of coliforms and intestinal pathogens in water, dairy 
products and biological specimens 
 
Preparation of MacConkey Agar 
1. Suspend 49.53 grams of dehydrated medium in 1000 ml purified/distilled water 
2. Heat to boiling to dissolve the medium completely 
3. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes 
4. Cool to 45-50°C 
5. Mix well before pouring into sterile Petri plates 
6. Result Interpretation on MacConkey Agar 
7. Lactose fermenting strains grow as red or pink and may be surrounded by a zone 
of acid precipitated bile. The red colour is due to production of acid from lactose, 
absorption of neutral red and a subsequent colour change of the dye when the pH of 
medium falls below 6.8 
8. Lactose non-fermenting strains, such as Shigella and Salmonella are colourless and 
transparent and typically do not alter appearance of the medium. Yersinia 
enterocolitica may appear as small, non-lactose fermenting colonies after incubation 
at room temperature 
TABLE: 3 
Colony Morphology on MacConkey Agar 
Organism Colour Remarks 
Escherichia coli Red/Pink Non-mucoid 
Aerobacteraerogenes Pink Mucoid 
Enterococcus species Red Minute, round 
Staphylococcus species Pale pink Opaque 
Pseudomonas aeruginosa Green-brown Fluorescent growth 
 
Following inoculation, the plates were incubated in a bacteriological incubator at 370° C and 
after overnight incubation and after 48 hours the plates were checked. If bacterial growth was 
obtained on the plates, the colony count was first estimated by counting the number of 
colonies in the streaked area of the plate and multiplying the same by 10.  
 
A smear of an individual colony was prepared on a microscope slide, and this was stained by 
the gram method, dried and viewed under the oil immersion objective or a light microscope. 
If positive, with the presence of beta haemolysis on blood agar and growth on MacConkey 
agar, the growth was considered to be staphylococcus aureus. If coagulase test was negative, 
with no beta haemolysis on blood agar and no growth on MacConkey agar, the growth was 
considered to be a coagulase‐negative staphylococcus. 
 Fig.  17 
 
Colony Morphology on MacConkey Agar 
 
 
 
Penetration (Aqueous) 
The patients were instructed to use their antibiotic drops according to Regimen A or B to 
which they were assigned. During surgery 0.2 ml of aqueous humour was aspirated with the 
help of a tuberculin syringe. The anterior chamber fluid was immediately placed into a 
sterilized cryogenic tube and stored at ‐40° C in a refrigerator and kept frozen until analysis 
was performed. Each tube was marked with a patient identification number (which indicated 
the antibiotic that the subject was randomly assigned), the subject's initials, date of surgery, 
and eye (R/L).  
Concentrations of topically applied fluoroquinolones were determined by use of 
reverse‐phase high pressure liquid chromatography (HPLC) assay technique with ultraviolet–
visible detector at a wavelength of 275 nm. 
Chromatographic Conditions for Besifloxacin 
 
       Stationary Phase        :   Phenomenex 250×4.60 mm 5 micron 
       Mobile Phase             :   Acetonitrile ː   Water 
       Mobile phase ratio     :   90:10% v/v 
       Flow rate                    :   1.0 ml/min 
       Sample volume          :   10µl 
       Detection                   :    275nm using UV Visible detector 
       Software                    :    LC Real time analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Result & Discussion  
VIII. RESULT & DISCUSSION 
Table - 4 
Categorization of patients according to Age - Regimen  A 
(n=25) 
AGE ( in yrs) No. of PATIENTS PERCENTAGE (%) 
30-39 1 4% 
40-49 0 Nil 
50-59 10 40% 
60-69 8 32% 
70-79 6 24% 
80-89 0 Nil 
 
Fig.  18 
 
 
Out of the selected 25 patients, 1 patient (4%) was in the age group of 30-39 years, no patient 
was in the age group of 40-49 years, 10 patients (40%) were in the age group of 50-59 years, 
8 patients  (32%) were in the age group of 60-69 years and 6 patients (24%) were in the age 
group of 70-79 years; whereas no patient was in the group of 80-89 years of age. 
 
30-39 
40-49 
50-59 
60-69 
70-79 
Table - 5 
Categorization of patients according to Age - RegimenB 
(n=25) 
AGE (in yrs) No. of PATIENTS PERCENTAGE (%) 
30-39 0 Nil 
40-49 4 16% 
50-59 8 32% 
60-69 7 28% 
70-79 4 16% 
80-89 2 8% 
 
Fig.  19 
 
 
Out of the selected 25 patients, no patient was in the age group of 30-39 yrs; 4 patients (16%) 
were in the age group of 40-49 years, 8 patients (32%) were in the age group of 50-59 years, 
7 patients  (28%) were in the age group of 60-69 years, 4 patients (16%) were in the age 
group of 70-79 years, and 2 patients (8%) were in the age group of 80-89 years. 
 
 
 
40-49 
50-59 
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80-89 
Comparison of Age (in yrs) between Regimen A and B 
 
Fig.  20 
 
 
In Regimen – A, out of the selected 25 patients, 1 patient (4%) was in the age group of 30-39 
years, no patient was in the age group of 40-49 years, 10 patients (40%) were in the age 
group of 50-59 years, 8 patients  (32%) were in the age group of 60-69 years and 6 patients 
(24%) were in the age group of 70-79 years; whereas no patient was in the group of 80-89 
years of age. 
And in Regimen – B, out of the selected 25 patients, no patient was in the age group of 30-39 
yrs; 4 patients (16%) were in the age group of 40-49 years, 8 patients (32%) were in the age 
group of 50-59 years, 7 patients  (28%) were in the age group of 60-69 years, 4 patients 
(16%) were in the age group of 70-79 years, and 2 patients (8%) were in the age group of 80-
89 years. 
 
As is seen Regimen A didn’t have any patient in the group of 40-49 years of age and 80-89 
years, while the second Regimen didn’t have any patient in the age group of 30-39 years. In 
the rest of the age groups both regimens had almost equal distribution of patients, thereby 
nullifying any possible variability.  
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Table- 6 
Gender wise categorization of patients in Regimen – A 
(n=25) 
GENDER No. of PATIENTS 
 
PERCENTAGE (%) 
Male 11 
 
48 
Female 14 
 
56 
 
 
Fig. 21 
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Table-7 
Gender wise categorization of patients in Regimen – B(n=25) 
GENDER No.of PATIENTS 
 
PERCENTAGE(%) 
Male 13 
 
52 
Female 12 
 
48 
 
Fig.  22 
 
 
Fig.  23 
Comparison between Gender classes in Regimen-A &B 
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In Regimen A, out of the selected 25 patients, 11 patients (48%) were males and the 14 
patients (56%) were females; whereas in Regimen B, out of the selected 25 patients,13 
patients (52%) were males and the 12 patients (48%) were females, showing almost equal 
distribution of genders in both the regimens. 
 
Result of Associated disease conditions secondarily causing Cataract: 
Cataract secondary to other disorders include not only diabetes but also hyper tension alone 
or hyper tension with diabetes, and anaemia. Not only do diabetics develop cataracts earlier, 
they are more likely to suffer complications associated with cataract surgery. For this reason, 
considerable research has been performed to better understand why diabetics develop lens 
changes.  
Several concerns with diabetics: 1). Diabetics do not process glucose normally. The enzyme 
aldose reductase changes glucose to sorbitol through the polyol pathway. Sorbitol should be 
changed to fructose by the enzyme sorbitol dehydrogenase, but the sorbitol is produced faster 
than it can be converted to fructose, causing a buildup of sorbitol in the lens. Accumulation of 
sorbitol leads to increased water within the lens, changing the lens fiber array and formation 
of sugar cataracts.2). Osmotic stress caused by the sorbitol accumulation causes death of lens 
epithelial cells leading to the development of cataract. 
Table- 8 
Categorization of patients according to Associated diseases 
Each Regimen (n=25) 
 
ASSOCIATED 
DISEASES 
 
REGIMEN – A 
 
 
REGIMEN – B 
No. of 
Patients 
Percentage  
(%) 
No. of 
Patients 
Percentage  
(%) 
 
Diabetes 
 
3 
 
12 
 
4 
 
16 
 
Hypertension 
 
2 
 
8 
 
5 
 
20 
Diabetes with 
hypertension 
 
3 
 
12 
 
3 
 
12 
 
Anaemia 
 
7 
 
28 
 
          8 
 
32 
 
 
Fig.  24 
 
Categorization of patients according to Associated diseases 
Each Regimen (n=25) 
 
 
In Regimen-A, out of the selected 25 patients, 3 patients (12%) were Diabetic, and 2 patients 
(8%) were Hypertensive, 3 patients (12%) were both Diabetic and hypertensive and 7 patients 
(28%) were found to have Anemia.Out of the selected 25 patients in Regimen-B, 4 patients 
(16%) were Diabetic, and 5 patients (20%) were Hypertensive, 3 patients (12%) were both 
Diabetic and hypertensive and 8 patients (32%) were found to be Anemic. 
Results of Microbial isolates study: 
To study the nature and frequency of bacterial contamination during cataract surgery, we 
have taken preoperative smears from the conjunctiva and anterior chamber (AC) fluid 
aspirates during extra-capsular cataract surgery (ECCE) with posterior chamber intraocular 
lens (PCIOL) implantation in all the 50 eyes for aerobic and anaerobic bacteria. Any change 
in the bacterial strains isolated before and after cataract surgery was also studied and results 
presented here.  
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Table-9 
Categorization of patients in both the study teams according to Microbes isolated 
Each Regimen (n=25) 
 
MICRO ORGANISMS 
ISOLATED 
 
REGIMEN - A REGIMEN – B 
No. of 
PATIENTS 
PERCENTAGE  
(%) 
No. of 
PATIENTS 
 
PERCENTAGE 
(%) 
 
Staphylococcus albus 
 
15 
 
60 % 
 
6 
 
24 % 
 
Staphylococcus aureus 
 
12 
 
48 % 
 
16 
 
64 % 
 
Proteus vulgaris 
 
10 
 
40 % 
 
16 
 
64 % 
 
Klebsiella aerogenes 
 
5 
 
20 % 
 
4 
 
16 % 
 
Bacillus cereus 
 
2 
 
8 % 
 
6 
 
24 % 
 
Brucella sps. 
 
0 
 
Nil 
 
2 
 
8 % 
 
Micrococci 
 
2 
 
8 % 
 
0 
 
Nil 
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In Regimen – A, out of the selected 25 patients, 15 patients (60%) had Staphylococcus albus, 
12 patients (48%) had Staphylococcus aureus, 10 patients (40%) had Proteus vulgaris,          
5 patients (20%) had Klebsiella aerogenes and 2 patients (8%) had Micrococci. 
In Regimen - B, out of the selected 25 patients, 6 patients (24%) had Staphylococcus albus, 
16 patients (64%) had Staphylococcus aureus, 16 patients (64%) had Proteus vulgaris,                
4 patients (16%) had Klebsiella aerogenes, 6 patients (24%) had Bacillus cereus and               
2 patients (8%) had Brucella sps. 
Coagulase-negative Staphylococcus was the most common aerobe (60 %)and S. aureus was 
the most common facultative anaerobe. Of the total of 50 cases, 2 showed an organism 
different from other conjunctival smear. These two were Micrococci that was isolated under 
Regime – B patients. Clinically there was no endophthalmitis in any of the eyes. Factors such 
as preoperative antibiotic use, the antibacterial properties of aqueous, or low inoculum size 
could explain this. The preoperative conjunctival smear may not be useful in predicting the 
AC fluid contamination or outcome of cataract surgery. 
It has been postulated that the anterior chamber (AC) remains sterile during cataract 
extraction. Hara and coworkers (1997)have investigated the changes in the bacterial strains 
present before and after cataract surgery and found that preoperative cultures are not a useful 
guide to predict the organism responsible for postoperative infections. But more recently 
other investigators have demonstrated that bacteria routinely enter the AC during cataract 
surgery.  
Results of Types of cataracts done:  
Types of Cataracts include: 
 A subcapsular cataract occurs at the back of the lens. People with diabetes or those 
taking high doses of steroid medications have a greater risk of developing a 
subcapsular cataract – also called Posterior subcapsular cataract (PSC) 
 A nuclear cataract forms deep in the central zone (nucleus) of the lens. Nuclear 
cataracts usually are associated with aging – also referred to as Nuclear sclerosis 
grade cataract (NSG) 
 An immature Cataract - a cataract is considered immature when there are some 
remaining clear areas in the lens.  
 A mature Cataract is completely opaque. 
 TABLE - 10 
Categorization of patients according to Diagnosis in Regimen – A  
(n=25) 
Out of selected 25 patients, 7 patients (28%) were Posterior subcapsular cataract,10 patients 
(40%) were Nuclear sclerosis grade cataract and the remaining 8 patients (32%) were of 
Immature cataract. There was no case of Mature cataract in Regimen – A group. 
 
DIAGNOSIS No. of 
PATIENTS 
PERCENTAGE  
(%) 
 
Posterior subcapsular cataract (PSC) 
 
7 
 
28% 
 
Nuclear sclerosis grade cataract (NSG) 
 
10 
 
40% 
 
Immature cataract (IMC) 
 
8 
 
32% 
 
Mature cataract (MC) 
 
Nil 
 
-- 
 
Fig. 26 
Diagnosis-wise Categorization of Regimen- A 
(n=25) 
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 TABLE - 11 
Categorization of patients according to Diagnosis in Regimen – B 
(n=25) 
Out of selected 25 patients, 7 patients (28%) were Posterior sub capsular cataract,13 patients 
(52%) were Nuclear sclerosis grade cataract, 3 patients (12%) were Immature cataract and the  
2 patients (8%) were Mature cataract. 
 
 DIAGNOSIS  No OF 
PATIENTS 
PERCENTAGE  
(%) 
 
Posterior sub capsular cataract (PSC) 
 
7 
 
28% 
 
Nuclear sclerosis grade cataract (NSG) 
 
13 
 
52% 
 
Immature cataract (IMC) 
 
3 
 
12% 
 
Mature cataract (MC) 
 
2 
 
8% 
 
Fig. 27 
Diagnosis-wise Categorization of Regimen- B 
(n=25) 
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Comparison between Diagnosis-wise Categories in Regimen A and Regimen B 
 
In this study, it has been found that three types of Cataracts namely the Posterior Subcapsular 
Cataract (PSC), nuclear sclerosis grade cataract (NSGC) and immature senile cataract(IMSC) 
were the abundantly occurring types in both the study batches. Two cases of mature senile 
cataract (MSC) were seen in Regimen – B; whereas no case of hyper mature senile cataract 
(HMSC) was seen in either of the groups.    
Results of the study on the penetration of Besifloxacin in the aqueous humour in anterior 
chamber by using a High Pressure Liquid Chromatography (HPLC) analyzer: 
Table – 12 
 Mean Penetration of Besifloxacin - Regimen–A(n=25)  
DIAGNOSIS 
No. of 
PATIENTS 
EFFICACY 
PENETRATION  
(%) 
Posterior sub capsular 
cataract 
7 
Slight microbial growth is 
seen in 1patient (#-24) 
72.9 % 
(Min- 52.3%)(Max- 9.75%) 
Nuclear sclerosis 
grade cataract 
10 Nil growth 
69% 
(Min-52.7%)(Max-93.3%) 
Immature cataract 8 
Slight microbial growth is 
seen in 1patient  
(Sample #-15) 
69.1% 
(Min- 52.0%)(Max- 95%) 
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Table – 13 
 Mean Penetration of Besifloxacin in different types of Cataract - Regimen- B 
(n=25)  
DIAGNOSIS 
No. OF 
PATIENTS 
EFFICACY PENETRATION (%) 
Posterior sub capsular 
cataract 
7 
Slight microbial growth is 
seen in 2 patients  
(Sample #- 5 & 20) 
74.8% 
(Min-57.4%)(Max-89.2 %) 
Nuclear sclerosis 
grade cataract 
13 
Matty growth is seen in 
Sample # 2, 3, 14 & 16 
78.4% 
(Min-59.1%)(Max-95.3 %) 
Immature cataract 3 No Growth 
70.7% 
(Min-31.4%)(Max- 82.3%) 
Mature Cataract 2 
Slight growth is seen in 
Sample # 6 
61.9% 
(Min-54.7%)(Max- 86.7%) 
 
 
Table - 14 
Overall Percentage of drug penetration in Aqueous humour both in 
Regimen-A and Regimen-B 
 
REGIMEN–A REGIMEN – B 
 
 
70.30% 
 
74.97% 
 
 
 
 
 
 
Fig.  29 
 
Conjunctival base-line bacterial load seen on Two different Agar Plates - Regimen A 
 
 
 
 
 
In Regimen – A, out of the 25 patients  the base line bacterial load was found to be between  
5 to 5,000 Colony Forming Units (CFUs) in Nutrient agar plate and 5 to 10,000 CFUs in 
MacConkey agar medium. 
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Conjunctival base-line bacterial load seen on Two different Agar Plates  - Regimen B 
 
 
 
 
Out of the selected 25 patients, the base line bacterial load was found to be between 1 to 
1100 Colony Forming Units in Nutrient agar and 1 to 1000 CFUs in MacConkey agar 
medium. 
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Conjunctival pre-operative bacterial load seen on two different Agar Plates after 
Besifloxacin administration – Regimen B 
 
 
 
Out of the selected 25 patients, the pre-operative bacterial load was found to be between 1 to 
100 CFUs in Nutrient agar and  1 to 1000 Colony Forming Units in MacConkey medium.  
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In the Colony Forming Units (CFUs) count on Nutrient agar plates and MacConkey agar 
plates, the base-line count in patients of Regimen-A was found to be between5 to 5,000 CFUs 
in Nutrient agar and 5 to 10,000 CFUs in MacConkey agar medium. In the case of Regimen-
B, the base line bacterial load was found to be between 1 to 1100 CFUs in Nutrient agar and 
1 to 1000 CFUs in MacConkey agar medium.  
Whereas the pre-operative colony count showed ‘ nil growth’ in Regimen-A and a drastic 
reduction in case of pulse mode of administration i.e., in Regimen-B was noticed. Thereby it 
is seen that Regimen A shows a better antimicrobial effect locally on the cornea whereas the 
aqueous humor penetration was better in the case of Regimen B.            END 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Conclusion 
IX. CONCLUSION 
 
Prophylactic antibiotic eye drops are routinely used to prevent postoperative complications 
like endophthalmitis. Fluoroquinolones in particular have been used extensively due to their 
excellent activity against ocular pathogens, including both Gram-positive and Gram-negative 
bacteria. Selection of the most appropriate antibiotic should be based on considerations of 
pharmacodynamic and pharmacokinetic properties; namely, an agent with a broader 
spectrum, lower minimum inhibitory concentration (MIC) against pathogens, and better 
achievable concentration levels in the intraocular tissues should be the agent of choice to 
achieve optimal efficacy.  
To summarize current understanding of antibiotic prophylaxis in cataract surgery, with 
particular emphasis on available evidence and change in practice patterns over the past 
decade, the fourth generation fluoroquinolone - Besifloxacin was taken up here for 
determining its antimicrobial potency in the cornea and its ability to penetrate into the 
anterior chamber. 
 
 Results of the present study revealed no association between the grade of cataract and 
risk factors such as age, duration of diabetes or gender as evident from the correlation 
coefficient analysis.  
 
 NSGC - the Nuclear sclerosis graded cataract emerged as the most commonly found 
cataract in this hospital. This is followed by PSC – the Posterior subcapsular cataract. 
 
 Besifloxacin, the 4th Gen fluoroquinolone, penetrates the conjunctiva when applied 
topically to the extent of 70.30 % in conventional mode of administration and 74.97 
% in the pulse mode of instillation.  
 
 With the normal antimicrobial range of Besifloxacin, it is expected to prevent post-
surgical endophthalmitis to a great extent.   
   
 It’s clearly seen that pulse mode of administration of topical antibiotics an hour 
preceding surgery shows better penetration of the drug than administered with 
conventional style of two days prior to surgery.  
However, there are few studies that have clearly assessed the superiority of one drug over the 
other among the newer fourth-generation  fluoroquinolones, including  moxifloxacin and 
gatifloxacin, when used in humans.  Based on current evidence from this study, the 
recommended measures for endophthalmitis prophylaxis are preoperative topical instillation 
of fluoroquinolone antibiotic and if need be, intra caramel injection at the end of cataract 
surgery. 
 
WHETHER CATARACTS BE PREVENTED? 
Protecting the eyes from the sun's radiation with UV-filtering sunglasses may help slow the 
progression of cataracts. Controlling other eye diseases and quitting smoking if it is a smoker 
will also decrease the risk. 
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Appendices  
XI. APPENDICES 
PROFORMA-1 
 
INFORMED CONSENT FORM 
 
PATIENT NAME :                                                       DATE: 
AGE/ SEX  :                                                           REF NO: 
 
        I was explained about the description of the research study and they have answered all 
the questions I have at this time. 
        I freely volunteer to participate in this study. I understand that I do not have to take part 
in this study and that my refusal to participate will involve no penalty. Further I understand 
that I am free to discontinue participation from this study at any time. 
 
Clinician’s Name with signature                      Signature of the Patient 
 
mwptpf;fg;gl;l KbT 
 
Nehahspapd; ngah; :      Njjp : 
taJ/ ghypdk;   :     gjpT vz; : 
 
vdf;F Muha;r;rp Ma;T tpsf;fk; gw;wp KOtJkhf tpsf;fpaNjhL> ehd; Nfl;l 
midj;J re;Njfq;fSf;Fk; jpUg;jpfukhf gjpy; mspj;jdh;. 
ehd; KOkdjhf ,e;j Ma;tpy; gq;Nfw;f rk;kjpf;fpNwd;. ,e;j Ma;tpy; vd; gq;Nfw;G 
fl;lhagLj;jgltpy;iy vdTk;> ,jpy; ehd; gq;Nfw;f;f kWg;gjpdhy; vdf;F mguhjk; 
vJTk; ,y;iy vdTk;> kw;wk; ,e;j Ma;tpy; ,Ue;J ve;j NeuKk; ehd; 
tpyfpf;nfhs;s vdf;F chpik cz;L vd;gijAk;> ehd; Ghpe;J nfhz;Nld;.  
 
kUj;Jthpd; ngah;      Nehahspapd; ifnahg;gk; 
 
PROFORMA-2 
 
                                                   PATIENT PARTICULARS 
 
NAME     :                                                         
AGE      : 
SEX      : 
DATE      :                                                                                
REFERENCE NO    : 
CONSULTANT’S NAME   : 
MEDICAL HISTORY   : 
 
 
PRESENT COMPLAINTS   : 
 
 
 
ON EXAMINATION    : 
 
 
 
DIAGNOSIS     : 
 
OTHER INVESTIGATIONS   : 
 
 
 
PROFORMA-3 
 
                                    SURGICAL PROCEDURE PARTICULARS 
 
TYPE OF OPERATION   : 
 
 
ANESTHESIA    :        Yes  /   No   /   Standby 
DATE OF SURGERY   : 
 
EYE      :          Right  /  Left 
 
TYPE OF LENS    :                                    POWER : 
 
DRUG      :           Besifloxacin E/D 
 
DOSAGE REGIMEN    :       A  /  B 
 
COURSE IN HOSPITAL   : 
 
 
 
 
 
 
 
 
PROFORMA-4 
 
MEDICATION DETAILS 
 
REGIME-A 
S,NO DATE MEDICATION QTY/DOSE TIMING ROUTE FREQUENCY 
1   
 
 
Besifloxacin 
 
 
 
 
    
      
      
      
2      
      
      
      
 
 
REGIME-B 
S.NO DATE MEDICATION QTY/DOSE TIMING ROUTE FREQUENCY 
1   
 
Besifloxacin 
 
    
2      
3      
4      
5      
6      
 
 
 
 
 
 
 
